CYBER CARE INC Form 10QSB November 20, 2002

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2002 [] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to___ Commission file number 0-20356 _____ CYBERCARE, INC. _____ (Exact name of registrant as specified in its charter) FLORIDA 65-0158479 _____ _____ (State or other jurisdiction (IRS Employer Identification No.) incorporation or organization) 2500 QUANTUM LAKES DRIVE, SUITE 1000, BOYNTON BEACH, FLORIDA 33426-8330 _____ (Address of principal executive offices) (561) 742-5000 _____

(Registrant's telephone number)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such report(s)), and (2) has been subject to such filing requirements for the past 90 days. Yes X No ____

The registrant has one class of common stock, \$0.0025 par value, of which 77,653,192 shares were outstanding as of October 31, 2002.

CYBERCARE, INC.

10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2002

TABLE OF CONTENTS

| | E | AGE NO. |
|--|---|--|
| PART I. | FINANCIAL INFORMATION | |
| Item 1. | Condensed Consolidated Financial Statements | |
| | Condensed Consolidated Balance Sheets as of September 30, 2002 (unaudited) and December 31, 2001 | 3 |
| | Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2002 and 2001 (unaudited) | 4 |
| | Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2002 and 2001 (unaudited) | 5 |
| | Notes to Condensed Consolidated Financial Statements | 7 |
| Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 16 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 26 |
| Part II. | OTHER INFORMATION | |
| Item 2. Item 3. Item 4. Item 5. | Legal Proceedings Changes in Securities and Use of Proceeds Defaults Upon Senior Securities Submission of Matters to a Vote of Security Holders Other Information Exhibits and Reports on Form 8-K | 27 28 28 28 28 28 28 |
| Signatur | res | 30 |

2

CYBERCARE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share data)

> September 30, 2002 ----(unaudited)

ASSETS

Current Assets: Cash and cash equivalents Cash - restricted

| of 92,197 (2002) and 91,999 (2003) 1,317 Inventories, net 3,090 Notes receivable - related partles, less allowance of 9725 (2002) and 3,090 S604 (2001) to reduce to realizable value 3,090 Notes and interest receivable 3,090 Other current assets 6,551 Property and equipment, net 2,967 Conduit, not 2,967 Other assets 1,073 Total assets 3,19,487 Current liabilities 3,182 Accrued liabilities 6,722 Current liabilities 6,722 Current portion of notes payable and long-term debt 100 Lines of credat 702 Convertible subordinated debentures, net of discounts of \$45 5,456 Notes receive adde along-term debt 134 Convertible subordinated debentures, net of discounts of \$1,344 (2002) 10,510 and \$1,924 (2001) 10,510 Notes receives and contingencies 128 Stockholders' (neficit) Equity: 170 Total current liabilities 129 Convertible subordinated debentures, net of discounts of \$1,344 (2002) 10,510 <td< th=""><th>Trade accounts receivable, less allowance for doubtful accounts</th><th></th></td<> | Trade accounts receivable, less allowance for doubtful accounts | |
|--|---|----------|
| Notes receivable - related parties, less allowance of \$725 (2002) and \$504 (2001) to reduce to realizable value Notes and interest receivable Other current assets 93 Total ourrent assets 6,561 Property and equipment, net Goodvill, met 1,907 Inceress, net 7,056 Notes receivable 2,867 Other assets 1,907 Convertible 2,867 Other assets 1,033 Inceress, net 7,056 Notes receivable 6,722 Current liabilities 1,033 Accounts payable 6,725 Current liabilities 1,033 Convertible subcordinated dehentures, net of discounts of \$45 5,456 Net liabilities 1,639 Other current liabilities 1,630 Other current liabilities 1,630 Other current liabilities 1,630 | | 1,317 |
| \$604 (2001) to reduce to realizable value 93 Notes and interest receivable 1,096 Other current assets 367 Total current assets 367 Total current assets 6,561 Property and equipment, net 1,907 Goodedil, net 7,066 Nates area instantiation 2,867 Other assets 1,073 Total assets 2,867 Current liabilities: 4,073 Accounds payable 6,722 Current potion of notes payable and long-term debt 100 Lines of credit 702 Convertible subordinated debentures, net of discounts of 545 5,456 Netes and continued operations 1,669 Deferred revenue 100 Other ourrent liabilities 18,115 Convertible subordinated debentures, net of discounts of \$1,344 (2002) 10,510 Notes angule and long-term debt, net of current portion 10 Other ourrent liabilities 10 Convertible subordinated debentures, net of discounts of \$1,344 (2002) 10,510 Notes angule and long-term debt, net of current portion 10 Other ourcent liabilities 10 Convertible subordinated debentures, net of discounts of \$1,344 (2002) 10,510 Other for insuance <t< td=""><td>Inventories, net</td><td>3,090</td></t<> | Inventories, net | 3,090 |
| Notes and interest receivable 1,096 Other current assets 6,561 Freperty and equipment, net 6,561 Freperty and equipment, net 7,035 GoodWill, net 2,867 Licenses, net 7,036 Notes receivable 2,867 Cher assets 1,073 Total assets 519,467 LIABILITIES AND STOCKHOLDERS' EQUITY | | |
| Other current assets 367 Total current assets 6,561 Property and equipment, net 1,907 Goodwill, net 7,066 Notes receivable 7,066 Other assets 1,073 Total assets 21,073 LIABILITIES AND STOCKHOLDERS' EQUITY | | |
| Total current assets 6,561 Property and equipment, net 1,907 Goodwill, net 7,036 Licenzes, net 7,036 Notes receivable 2,867 Other assets 1,003 Total assets 1,003 LIABILITIES AND STOCKHOLDERS' EQUITY | | • |
| Total current assets6,561Property and equipment, net Coodwill, net Licenses, net Notes receivable1,907 23 23 23 23 23 23 23 23 23 | Other current assets | |
| Goodwill, net 23 Licensea, net 7,056 Notes receivable 2,667 Other assets 1,073 Total assets LIABULITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accound payable Accound payable and long-term debt 130 100 Lines of credit 100 Convertible subordinated debentures, net of discounts of \$45 5,456 Net liabilities 20 Other current liabilities 18,115 Convertible subordinated debentures, net of discounts of \$1,344 (2002) 10,510 Notes payable and long-term debt, net of current portion 20 Other current liabilities | Total current assets | |
| Goodwill, net 23 Licensea, net 7,056 Notes receivable 2,667 Other assets 1,073 Total assets LIABULITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accound payable Accound payable and long-term debt 130 100 Lines of credit 100 Convertible subordinated debentures, net of discounts of \$45 5,456 Net liabilities 20 Other current liabilities 18,115 Convertible subordinated debentures, net of discounts of \$1,344 (2002) 10,510 Notes payable and long-term debt, net of current portion 20 Other current liabilities | Property and equipment, net | 1,907 |
| Licenses, net 7,055 Notes receivable 7,056 Other assets 7,056 Cher assets 7,056 Total assets 7,057 Total assets 7,056 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: 7,057 Accounts payable And long-term debt 1,057 Current portion of notes payable and long-term debt 1,059 Deformed revenue 0,15,455 Convertible subordinated debentures, net of discounts of \$45 Notes payable and long-term debt 1,689 Deformed revenue 20 Other current liabilities 1,699 Deformed revenue 20 Other current liabilities 1,699 Deformed revenue 20 Other liabilities 1,699 Deformed revenue 20 Other liabilities 20 Commutments and contingencies 20 Stockholders' (Deficit) Equity: Preferred stock, 20,000,000 shares authorized; 19,800,000 shares available for issuance 20 Common stock, \$0,025 par value, 200,000,000 shares authorized; 19,800,000 shares available for issuance 20 Common stock, \$0,022 and December 31, 2001, respectively 21,929 Gapital in excess of par 2129,993 Stock suboription receivable 4, (4,740) Accounulated deficit (134,663) Total liabilities and stockholders' (deficit) equity 5, 19,487 | | • |
| Other assets 1,073 Total assets 119,487 LIABILITIES AND STOCKHOLDERS' EQUITY 119,487 Current liabilities: 6,722 Accound payable 6,722 Current portion of notes payable and long-term debt 102 Lines of credit 102 Convertible subordinated debentures, net of discounts of \$45 8,456 Net liabilities of discontinued operations 16,689 Deferred revenue 20 Other current liabilities 154 Total current liabilities 18,115 Convertible subordinated debentures, net of discounts of \$1,344 (2002) 10,510 and \$1,924 (2001) 10,510 Notes payable and long-term debt, net of current portion 29 Other liabilities 100 Total liabilities 100 Total liabilities 100 Commitments and contingencies 100 Stockholders' (Deficit) Equity: 103 Preferred stock, 20,000,000 shares authorized; 19,800,000 shares available for issuance - Common stock, 20,002,000 shares lasued and outstanding at September 30, 2002 and December 31, 2001, respectively 193 Capital in excess of | | 7,056 |
| Total assets 519,487 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable Accrued liabilities Convertible subordinated debentures, net of discounts of \$45 Net liabilities of discontinued operations Deferred revenue Other current liabilities Total current liabilities Convertible subordinated debentures, net of discounts of \$1,344 (2002) and \$1,324 (2001) Notes payable and long-term debt, net of current portion Other liabilities Commutments and contingencies Stockholders' (Deficit) Equity: Preferred stock, \$0,0025 par value, 200,000 shares authorized; 77,559,192 and 61,323,792 shares issued and outstanding at September 30, 2002 and December 31, 2001, respectively Gapital in excess of par Stock kolserly (deficit) equity Total liabilities (deficit) equity Total liabilities and stockholders' (deficit) equity Total liabilities and stockholders' (deficit) equity Stock subscription receivable Total liabilities and stockholders' (deficit) equity Total liabilities and stockholders' (deficit) equity Stock subscription receivable Total liabilities and stockholders' (deficit) equity Stock subscription receivable Total liabilities and stockholders' (deficit) equity | | • |
| Total assets \$19,497 LIABLITIES AND STOCKHOLDERS' EQUITY \$3,182 Accounts payable \$100 Convertible subordinated debentures, net of discounts of \$45 \$456 Net liabilities \$1,639 Deferred revenue 20 Other current liabilities \$1,515 Convertible subordinated debentures, net of discounts of \$1,344 (2002) \$10,510 and \$1,924 (2001) \$10,510 Notes payable and long-term debt, net of current portion \$29 Other liabilities \$28,824 Commitments and contingencies \$28,824 Common stock, \$0,000,000 shares authorized; 19,800,000 shares authorized; 77,559,192 and 67,827,992 | Other assets | |
| LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accured liabilities Accured liabilities Accured liabilities Current portion of notes payable and long-term debt Lines of credit Convertible subordinated debentures, net of discounts of \$45 Net liabilities of discontinued operations Deferred revenue Convertible subordinated debentures, net of discounts of \$1,344 (2002) and \$1,924 (2001) Notes payable and long-term debt, net of current portion Cher liabilities Convertible and long-term debt, net of current portion Cher liabilities Convertible and contingencies Stockholders' (Deficit) Equity: Prefered stock, \$0,0002 par value, 200,0000 shares authorized; 77,559,192 and 67,827,992 shares issued and outstanding at Stock subscription receivable Accumulated deficit Cotal tiabilities and stockholders' (deficit) equity Capital in excess of par Cotal liabilities and stockholders' (deficit) equity Capital in excess of par Cotal liabilities and stockholders' (deficit) equity Capital in excess of par Cotal liabilities and stockholders' (deficit) equity Capital in excess of par Cotal liabilities and stockholders' (deficit) equity Capital in excess of par Cotal liabilities and stockholders' (deficit) equity Capital in excess of par Cotal liabilities and stockholders' (deficit) equity Capital in excess of par Cotal stockholders' (deficit) equity Capital in excess of par Cotal stockholders' (deficit) equity Capital in excess of par Cotal stockholders' (deficit) equity Capital in excess of par Cotal stockholders' (deficit) equity Capital in excess of par Cotal stockholders' (deficit) equity Capital in excess of par Cotal stockholders' (deficit) equity Capital in excess of par Cotal stockholders' (deficit) equity Capital in excess of par Cotal stockholders' (deficit) equity Capital in excess of par Cotal stockholders' (deficit) equity Capital in excess of par Cotal stockholders' (deficit) equity Capital in excess of par Cotal stockholders' (deficit) equity Capital in excess of par Cotal stockholders' (deficit) equity Capita | | |
| Current liabilities: Accounts payable Accrued liabilities Current portion of notes payable and long-term debt Lines of credit Convertible subordinated debentures, net of discounts of \$45 Net liabilities of discontinued operations Deferred revenue Other current liabilities Total current liabilities Convertible subordinated debentures, net of discounts of \$1,344 (2002) and \$1,924 (2001) Notes payable and long-term debt, net of current portion Other liabilities Total liabilities Stockholders' (Deficit) Equity: Preferred stock, 20,000,000 shares authorized; 19,800,000 shares available for issuance Common stock, 50,0025 par value, 200,000,000 shares authorized; 77,559,192 and 67,827,992 shares issued and outstanding at Stock subscription receivable Accure deficit Total stockholders' (deficit) equity Total stockholders' (deficit) equity Total liabilities and stockholders' (deficit) equity Stock aubscription stock, 50,0126 par 4 Common receivable Accure deficit Total stockholders' (deficit) equity Total liabilities and stockholders' (deficit) equity Stock subscription stock, 50,0126 par 5 Stockholders' (deficit) equity Total liabilities Addition for the stockholders' (deficit) equity Total liabilities Addition for the stockholders' (deficit) equity Stock subscription receivable Accure deficit Total liabilities and stockholders' (deficit) equity Stock subscription for for the stockholders' (deficit) equity Stock subscription for the stockholders' (deficit) equity Stock subscription for the stockholders' (deficit) equity Accure deficit Stock liabilities and stockholders' (deficit) equity Stock subscription for the stockholders' (deficit) equity | Total assets | • |
| Current liabilities: Accounts payable Accrued liabilities Current portion of notes payable and long-term debt Lines of credit Convertible subordinated debentures, net of discounts of \$45 Net liabilities of discontinued operations Deferred revenue Other current liabilities Total current liabilities Convertible subordinated debentures, net of discounts of \$1,344 (2002) and \$1,924 (2001) Notes payable and long-term debt, net of current portion Other liabilities Total liabilities Stockholders' (Deficit) Equity: Preferred stock, 20,000,000 shares authorized; 19,800,000 shares available for issuance Common stock, 50,0025 par value, 200,000,000 shares authorized; 77,559,192 and 67,827,992 shares issued and outstanding at September 30, 2002 and December 31, 2001, respectively Capital in excess of par Total stockholders' (deficit) equity Total stockholders' (deficit) equity Total liabilities and stockholders' (deficit) equity S 19,487 | | |
| Accounts payable\$3,182Accrued liabilities6,722Current portion of notes payable and long-term debt190Lines of credit702Convertible subordinated debentures, net of discounts of \$455,456Net liabilities of discontinued operations1,669Deferred revenue20Other current liabilities154Total current liabilities154Convertible subordinated debentures, net of discounts of \$1,344 (2002)10,510and \$1,924 (2001)10,510Notes payable and long-term debt, net of current portion29Other liabilities170Total liabilities28,824Commitments and contingencies19,800,000 sharesStockholders' (Deficit) Equity:19,800,000 shares authorized; 19,800,000 sharesPreferred stock, 20,000,000 shares authorized; 19,800,000 shares-77,559,192 and 67,827,992 shares issued and outstanding at September 30, 2002 and December 31, 2001, respectively Capital in excess of par Total stockholders' (deficit) equity193Stock subscription receivable Accumulated deficit(134,639)Total liabilities and stockholders' (deficit) equity\$ 19,487 | ~ | |
| Current portion of notes payable and long-term debt190Lines of credit702Convertible subordinated debentures, net of discounts of \$455,456Net liabilities of discontinued operations1,689Deferred revenue20Other current liabilities154Total current liabilities154Convertible subordinated debentures, net of discounts of \$1,344 (2002)10,510and \$1,924 (2001)10,510Notes payable and long-term debt, net of current portion29Other liabilities170Total liabilities170Commitments and contingencies28,824Stockholders' (Deficit) Equity:Preferred stock, 20,000,000 shares authorized; 19,800,000 shares available for issuance-Common stock, \$0.0025 par value, 200,000,000 shares authorized; 77,559,192 and 67,827,992 shares issued and outstanding at September 30, 2002 and December 31, 2001, respectively Capital in excess of par Stock subscription receivable Accumulated deficit193Total stockholders' (deficit) equity193Total stockholders' (deficit) equity | | \$3,182 |
| Lines of credit 702 Convertible subordinated debentures, net of discounts of \$45 Net liabilities of discontinued operations 20 Other current liabilities 1,689 Deferred revenue 20 Other current liabilities 154 Total current liabilities 164 Convertible subordinated debentures, net of discounts of \$1,344 (2002) and \$1,924 (2001) 10,510 Notes payable and long-term debt, net of current portion 29 Other liabilities 28,824 Total liabilities 28,824 Commitments and contingencies Stockholders' (Deficit) Equity: Preferred stock, 20,000,000 shares authorized; 19,800,000 shares available for issuance - Common stock, \$0.0025 par value, 200,000,000 shares authorized; 77,559,192 and 67,827,992 shares issued and outstanding at September 30, 2002 and December 31, 2001, respectively (134,683) Capital in excess of par (4,740) Accumulated deficit (134,683) Total stockholders' (deficit) equity \$ 19,487 | Accrued liabilities | 6,722 |
| Convertible subordinated debentures, net of discounts of \$455,456Net liabilities of discontinued operations1,689Deferred revenue20Other current liabilities | | |
| Net liabilities of discontinued operations1,689Deferred revenue20Other current liabilitiesTotal current liabilitiesTotal current liabilities154Convertible subordinated debentures, net of discounts of \$1,344 (2002)10,510and \$1,924 (2001)10,510Notes payable and long-term debt, net of current portion29Other liabilities | | |
| Deferred revenue 20 Other current liabilities 154 Total current liabilities 154 Is,115 Convertible subordinated debentures, net of discounts of \$1,344 (2002) and \$1,924 (2001) 10,510 Notes payable and long-term debt, net of current portion 29 Other liabilities 29 Other liabilities 28,824 | | |
| Other current liabilities 154 Total current liabilities 154 Total current liabilities 18,115 Convertible subordinated debentures, net of discounts of \$1,344 (2002) 10,510 and \$1,924 (2001) 10,510 Notes payable and long-term debt, net of current portion 29 Other liabilities Total liabilities Total liabilities 28,824 Commitments and contingencies Stockholders' (Deficit) Equity: Preferred stock, 20,000,000 shares authorized; 19,800,000 shares available for issuance Common stock, \$0.0025 par value, 200,000,000 shares authorized; 77,559,192 and 67,827,992 shares issued and outstanding at September 30, 2002 and December 31, 2001, respectively 193 129,893 Capital in excess of par (4,740) | - | • |
| Total current liabilities154 18,115Convertible subordinated debentures, net of discounts of \$1,344 (2002) and \$1,924 (2001)10,510 29 29 20 10,510 29 20 10,510 29Notes payable and long-term debt, net of current portion Other liabilities10,510 29 20 28,824 28,824 20Commitments and contingencies | | |
| Total current liabilities18,115Convertible subordinated debentures, net of discounts of \$1,344 (2002) and \$1,924 (2001)10,510 29Notes payable and long-term debt, net of current portion Other liabilities10,510 29Total liabilities 170 28,824Commitments and contingencies 28Stockholders' (Deficit) Equity: Preferred stock, 20,000,000 shares authorized; 19,800,000 shares available for issuance Common stock, \$0.0025 par value, 200,000,000 shares authorized; 77,559,192 and 67,827,992 shares issued and outstanding at September 30, 2002 and December 31, 2001, respectively Capital in excess of par Stock subscription receivable Accumulated deficit193 129,893 (134,663) (134,663) (134,663) (134,663)Total liabilities and stockholders' (deficit) equity\$ 19,487 | | |
| Convertible subordinated debentures, net of discounts of \$1,344 (2002) and \$1,924 (2001) 10,510 29 Other liabilities 2 Total liabilities 2 Commitments and contingencies Stockholders' (Deficit) Equity: Preferred stock, 20,000,000 shares authorized; 19,800,000 shares available for issuance - Common stock, \$0.0025 par value, 200,000,000 shares authorized; 77,559,192 and 67,827,992 shares issued and outstanding at September 30, 2002 and December 31, 2001, respectively (4,740) Accumulated deficit (134,663) Total stockholders' (deficit) equity \$ 19,487 | Total current liabilities | |
| and \$1,924 (2001) 10,510 Notes payable and long-term debt, net of current portion 29 Other liabilities 23,824 Total liabilities 28,824 Commitments and contingencies Stockholders' (Deficit) Equity: Preferred stock, 20,000,000 shares authorized; 19,800,000 shares available for issuance - Common stock, \$0.0025 par value, 200,000,000 shares authorized; 77,559,192 and 67,827,992 shares issued and outstanding at September 30, 2002 and December 31, 2001, respectively 193 Capital in excess of par 129,893 Stock subscription receivable (134,663) Accumulated deficit (134,663) Total stockholders' (deficit) equity (9,337) Total liabilities and stockholders' (deficit) equity \$ 19,487 | | 10,110 |
| Notes payable and long-term debt, net of current portion29Other liabilitiesTotal liabilitiesTotal liabilities28,824Commitments and contingenciesStockholders' (Deficit) Equity: Preferred stock, 20,000,000 shares authorized; 19,800,000 shares available for issuance Common stock, \$0.0025 par value, 200,000,000 shares authorized; 77,559,192 and 67,827,992 shares issued and outstanding at September 30, 2002 and December 31, 2001, respectivelyCapital in excess of par Stock subscription receivable Accumulated deficit(134,683)Total stockholders' (deficit) equityTotal liabilities and stockholders' (deficit) equity\$ 19,487 | Convertible subordinated debentures, net of discounts of \$1,344 (2002) | |
| Other liabilities 170 Total liabilities 28,824 Commitments and contingencies | | • |
| Total liabilities170Total liabilities28,824Commitments and contingencies19,800,000 sharesStockholders' (Deficit) Equity: Preferred stock, 20,000,000 shares authorized; 19,800,000 shares available for issuance-Common stock, \$0.0025 par value, 200,000,000 shares authorized; 77,559,192 and 67,827,992 shares issued and outstanding at September 30, 2002 and December 31, 2001, respectively193 129,893 Stock subscription receivable (4,740) Accumulated deficitTotal stockholders' (deficit) equity | | 29 |
| Total liabilities28,824Commitments and contingenciesStockholders' (Deficit) Equity: Preferred stock, 20,000,000 shares authorized; 19,800,000 shares available for issuance-Common stock, \$0.0025 par value, 200,000,000 shares authorized; 77,559,192 and 67,827,992 shares issued and outstanding at September 30, 2002 and December 31, 2001, respectively193 129,893 (4,740) Accumulated deficitTotal stockholders' (deficit) equity | other Habilities | |
| Commitments and contingencies Stockholders' (Deficit) Equity: Preferred stock, 20,000,000 shares authorized; 19,800,000 shares available for issuance - Common stock, \$0.0025 par value, 200,000,000 shares authorized; 77,559,192 and 67,827,992 shares issued and outstanding at September 30, 2002 and December 31, 2001, respectively 193 Capital in excess of par 129,893 Stock subscription receivable (4,740) Accumulated deficit (134,683) Total stockholders' (deficit) equity (9,337) Total liabilities and stockholders' (deficit) equity \$ 19,487 | | 170 |
| Stockholders' (Deficit) Equity: Preferred stock, 20,000,000 shares authorized; 19,800,000 shares available for issuance-Common stock, \$0.0025 par value, 200,000,000 shares authorized; 77,559,192 and 67,827,992 shares issued and outstanding at September 30, 2002 and December 31, 2001, respectively193 (20,893 (4,740) (4,740) Accumulated deficit193 (4,740) (134,683)Total stockholders' (deficit) equity | Total liabilities | 28,824 |
| Stockholders' (Deficit) Equity: Preferred stock, 20,000,000 shares authorized; 19,800,000 shares available for issuance-Common stock, \$0.0025 par value, 200,000,000 shares authorized; 77,559,192 and 67,827,992 shares issued and outstanding at September 30, 2002 and December 31, 2001, respectively193 (20,893 (20,893) (20,893) (20,893) (20,893) (20,740) Accumulated deficit193 (20,893) (4,740) (134,683)Total stockholders' (deficit) equity | | |
| Preferred stock, 20,000,000 shares authorized; 19,800,000 shares available for issuance - Common stock, \$0.0025 par value, 200,000,000 shares authorized; 77,559,192 and 67,827,992 shares issued and outstanding at September 30, 2002 and December 31, 2001, respectively 193 Capital in excess of par 129,893 Stock subscription receivable (4,740) Accumulated deficit (134,683) Total stockholders' (deficit) equity (9,337) Total liabilities and stockholders' (deficit) equity \$ 19,487 | Commitments and contingencies | |
| Preferred stock, 20,000,000 shares authorized; 19,800,000 shares available for issuance - Common stock, \$0.0025 par value, 200,000,000 shares authorized; 77,559,192 and 67,827,992 shares issued and outstanding at September 30, 2002 and December 31, 2001, respectively 193 Capital in excess of par 129,893 Stock subscription receivable (4,740) Accumulated deficit (134,683) Total stockholders' (deficit) equity (9,337) Total liabilities and stockholders' (deficit) equity \$ 19,487 | | |
| available for issuance-Common stock, \$0.0025 par value, 200,000,000 shares authorized; 77,559,192 and 67,827,992 shares issued and outstanding at September 30, 2002 and December 31, 2001, respectively193Capital in excess of par129,893Stock subscription receivable(4,740)Accumulated deficit(134,683)Total stockholders' (deficit) equityTotal liabilities and stockholders' (deficit) equity\$ 19,487 | | |
| Common stock, \$0.0025 par value, 200,000,000 shares authorized; 77,559,192 and 67,827,992 shares issued and outstanding at September 30, 2002 and December 31, 2001, respectively 193 Capital in excess of par 129,893 Stock subscription receivable (4,740) Accumulated deficit (134,683) Total stockholders' (deficit) equity | | _ |
| September 30, 2002 and December 31, 2001, respectively 193 Capital in excess of par 129,893 Stock subscription receivable (4,740) Accumulated deficit (134,683) Total stockholders' (deficit) equity (9,337) Total liabilities and stockholders' (deficit) equity \$ 19,487 | | |
| Capital in excess of par 129,893 Stock subscription receivable (4,740) Accumulated deficit (134,683) Total stockholders' (deficit) equity (9,337) Total liabilities and stockholders' (deficit) equity \$ 19,487 | | |
| Stock subscription receivable (4,740) Accumulated deficit (134,683) Total stockholders' (deficit) equity (9,337) Total liabilities and stockholders' (deficit) equity \$ 19,487 | | |
| Accumulated deficit (134,683) Total stockholders' (deficit) equity (9,337) Total liabilities and stockholders' (deficit) equity \$ 19,487 | | |
| Total stockholders' (deficit) equity Total liabilities and stockholders' (deficit) equity \$ 19,487 | | |
| (9,337) Total liabilities and stockholders' (deficit) equity \$ 19,487 | | |
| (9,337) Total liabilities and stockholders' (deficit) equity \$ 19,487 | Total stockholders' (deficit) equity | |
| | | |
| | Total liphilities and stackholdered (definit) emitted | ¢ 10 407 |
| | TOTAL TEADITITIES and SCOCKHOLGERS. (GELICIT) EQUILY | • |

See Notes to Condensed Consolidated Financial Statements.

3

CYBERCARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share data) (Unaudited)

| | Three Months Ended September 30, | | |
|---|-------------------------------------|----------|--|
| | 2002 | 2001 | |
| Net revenues | \$ 2,174 | \$ 3,918 | |
| | | | |
| Costs and expenses: | | | |
| Cost of services | 1,963 | 2,656 | |
| Selling, general and administrative | 2,270 | 4,403 | |
| Research and development | 426 | 2,513 | |
| Depreciation and amortization | 474 | 579 | |
| Impairment of long-lived assets | 2,525 | 2,525 | |
| | 2,020 | 2,020 | |
| Litigation and legal settlement costs | | | |
| Loss (gain) on sale of subsidiaries | | 754 | |
| Total costs and expenses | 7,658 | 10,151 | |
| Operating loss | (5,484) | (6,233) | |
| Other income (expense): | | | |
| Interest income | 150 | 263 | |
| Interest expense | (655) | (515) | |
| Amortization of beneficial conversion feature & | (293) | (215) | |
| liscount | | | |
| Other income | (168) | 79 | |
| Total other income (expense) | (966) | (388) | |
| Loss from continuing operations | (6,450) | (6,621) | |

| Estimated loss on disposal of discontinued business Cumulative effect on prior years of change in accounting | | (4) | | (1678) |
|---|-----------|---------------------|------------|-----------|
| for intangible assets | | (3,983) | | |
| Net loss | \$ === | (10,437) | \$ ==== | (8,299) |
| Loss per common share - basic and diluted: Loss from continuing operations | \$ | (0.09) | Ş | (0.10) |
| Discontinued operations Cumulative effect on prior years of change in | | | | (0.03) |
| accounting for intangible assets | | (0.05) | | |
| Net loss | \$ | (0.14) | Ş | (0.13) |
| Weighted average shares outstanding | 7 === | 3,187,818 ====== | | 5,823,776 |

See Notes to Condensed Consolidated Financial Statements.

4

CYBERCARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited)

| | Nine Mont Septem | |
|---|---------------------|------|
| | 2002 | |
| Cash Flows from Operating Activities: | | |
| Net loss | \$(22,616) | \$(2 |
| Adjustments to reconcile net loss to net cash used in operating activities: | | |
| Depreciation | 555 | |
| Amortization | 967 | |
| Provision for doubtful accounts | 2,617 | |
| Amortization of beneficial conversion feature and discount | 753 | |
| Loss from unconsolidated subsidiary | 16 | |
| Loss on disposal of fixed assets | 42 | |
| Impairment of long-lived Assets | 2,525 | |
| Cumulative effect on prior years of change in accounting | | |
| for intangible assets | 3,983 | |
| Common stock issued for services | 44 | |
| Amortization of deferred loan costs | 211 | |
| Common stock issued for interest | 215 | |
| Common stock issued for settlement of lawsuits | 1,004 | |
| Net liabilities of discontinued operations | 29 | |
| Warrants issued for services | | |

| Net assets of discontinued operations Estimated loss on disposal of discontinued business | | (|
|--|---------------------|-----------|
| Loss (gain) on sale of subsidiaries Changes in operating assets and liabilities, net of effects of dispositions: | 754 | |
| Trade accounts receivable | 98 | (|
| Inventories | (491) | (|
| Notes receivable and other current assets | 344 | Ň |
| Accounts payable | 496 | |
| Accrued and other current liabilities | 806 | |
| Net cash used in operating activities | (7,648) | (2 |
| Cash Flows from Investing Activities: | | |
| Purchase of marketable securities | | |
| Cash transferred upon sale of subsidiary | (64) | |
| Proceeds from sale of marketable securities | | |
| Restricted cash | 95 | |
| Repayment from related parties, net | 41 | |
| Capital expenditures | (152) | |
| Change in intangible, notes receivable and other assets | 265 | |
| Net cash provided by investing activities | 185 | |
| Cash Flows from Financing Activities: | | |
| Other liabilities | 184 | |
| Net borrowings under lines of credit | (272) | |
| Proceeds from exercise of stock options and warrants | (272) | |
| Proceeds from sale of common stock | 214 | |
| Proceeds from sale of convertible subordinated debentures | 6,964 | 1 |
| Net cash provided by financing activities | 7,090 | |
| Net decrease in cash and cash equivalents | (373) | (1 |
| Cash and cash equivalents at the beginning of period | 693 | 1 |
| Cash and cash equivalents at the end of period | \$ 319 | \$ |
| | | === |
| Supplemental disclosure of cash flow information: | | |
| Cash paid for interest | \$ 365 ====== | \$ === |

See Notes to Condensed Consolidated Financial Statements.

5

CYBERCARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS, Continued (In thousands) (Unaudited) Supplemental disclosures of non-cash investing and financing activities:

| | For the Ni September 30 2002 | ne Months Ended , September 3 2001 |
|---|------------------------------------|--|
| Fair market value of detachable warrants issued with convertible subordinated | \$ 126 301 | \$ 2,618 |
| Beneficial conversion feature on convertible debentures Common stock issued for payment of accounts payable Common stock issued for accrued contribution to retirement plan Common stock issued for settlement of lawsuit | 301 466 102 90 | 61 125 |
| Common stock received as consideration for sale of subsidiary | (692) | |
| Common stock issued for payment of accrued interest Common stock received in repayment of note receivable Common stock received in repayment of stock subscription receivable Common stock issued to purchase domain name | 323 16 | 366 (183) (65) |
| Common stock issued for stock subscription receivable Common stock issued on Conversion of Notes Payable Property and equipment included in other liabilities Common stock received upon incurred breach of contract | 175 (114) | 900 568 |

The following is a summary of the significant non-cash amounts that resulted from the Company's dispositions:

| Assets disposed: Accounts receivable Property and equipment Goodwill | 2002 |
|--|--------------------------|
| Accounts receivable Property and equipment | |
| Property and equipment | |
| Other assets | \$(196) (76) (412) |
| Assets disposed | (684) |
| Liabilities transferred: Accounts payable Accrued expenses and short-term debt | 64 20 |
| Liabilities transferred | 84 |
| Fair value of common stock issued | 600 |

Cash transferred upon dispositions \$--

6

CYBERCARE, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2002 (UNAUDITED)

Note 1 - Organization and Summary of Significant Accounting Policies

Organization

CyberCare, Inc. ("CyberCare" or the "Company") is a holding company, which consists primarily of service businesses including a physical therapy and rehabilitation business, a pharmacy business, and a healthcare technology solutions business. Our overall goal is to improve the delivery and quality of healthcare for patients while adding incremental value to our customers' clinical and business processes. Our physical therapy and rehabilitation business operates clinics in Southern Florida. Its staff of clinicians and therapists complement traditional primary care, orthopedic and neurological physician services and serve a wide range of patients requiring physical and occupational therapy and other rehabilitation services. Our pharmacy business supports patients and residents in assisted living and other long-term care facilities located in Florida. It also is licensed for mail order distribution across all fifty states.

Our healthcare technology business provides enabling technology by utilizing its intellectual property, including patented technology, to deliver tele-health solutions addressing the entire continuum of care. Its Electronic HouseCall(R) (EHC(TM)) hardware and software technology focuses on the chronically ill, wellness management and wound care. The EHC(TM) family of products and services permit enhanced physician supervision and oversight and enable remote medical and wellness monitoring and real-time interactive communications between patients and caregivers. This is made possible through various monitoring devices, hardware and software applications and our ability to establish an interactive network across the health care continuum and among a community of users and providers. In combination with our customers' clinical and business processes, the EHC(TM) System allows for effective and efficient data collection, integration and security, while successfully supporting case management and promoting personal participation and interaction.

Going Concern

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying condensed consolidated financial statements, the Company incurred a net loss for the nine months ended September 30, 2002 of \$22,616,000, negative cash flow from operating activities of \$7,649,000, a working capital deficiency of \$11,554,000 and certain loan covenant violations at September 30, 2002. These factors, among others, may indicate that the Company will be unable

to continue as a going concern for a reasonable period of time.

The condensed consolidated financial statements do not include any adjustments relating to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company's continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations, to obtain additional financing, and ultimately, to attain successful operations. There can be no assurances that such capital will be available to the Company on acceptable terms, or at all, or that the Company can attain successful operations. In addition, on November 1, 2002, the company's common stock was delisted from trading on the NASDAQ stock market (see note 6) which may make it more difficult for the Company to obtain additional financing or other capital.

Future Capital Needs

7

For the nine months ended September 30, 2002 and for the year ended December 31, 2001, the Company incurred operating losses and cash flow deficiencies. The Company expects to incur additional losses for the remainder of 2002 as it carries out its business plan. In order for the Company to generate additional needed cash flow, the Company is attempting to sell its various operating entities, and the proceeds received from the sale will be used for working capital purposes and reduction of existing liabilities. The Company may also raise funds through additional equity or debt financing. The Company is also continuing to reduce its overall monthly cash burn rate and management believes that it is at or near a cost level whereby it can sustain its operations, while at the same time seeking alternative funding sources. There is no assurance that the Company will be able to sell the non-tele-healthcare businesses, reduce its costs and expenses, or raise the necessary funds.

Basis of Presentation and Consolidation

The accompanying condensed consolidated financial statements have been prepared by the Company and are unaudited pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information related to the Company's significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted. In the opinion of management, these unaudited condensed consolidated financial statements reflect all material adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the consolidated financial position and consolidated results of operations for the interim periods presented. These results are not necessarily indicative of a full year's results of operations. Certain reclassifications have been made to the prior period financial statements to conform to the September 30, 2002 presentation.

Although the Company believes that the disclosures provided are adequate to make the information presented not misleading, these unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2001.

The Company's condensed consolidated financial statements include the activity of the Company and its wholly-owned subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation.

Cumulative Effect of Change in Accounting Principle

In June 2001, the Financial Accounting Standards Board ("FASB") issued

Statement of Financial Accounting Standards No. 142 ("SFAS 142"), "Goodwill and Other Intangible Assets". SFAS 142 requires that goodwill no longer be amortized to earnings, but instead be reviewed for impairment upon initial adoption of the Statement and on an annual basis going forward. SFAS 142 also requires the Company to complete a transitional goodwill impairment test six months from the date of adoption. The amortization of goodwill ceased upon adoption of SFAS 142 as of January 1, 2002 which will result in a reduction of the Company's amortization expense by approximately \$280,000 per year. The Company completed the transitional impairment test of goodwill and indefinite lived intangible assets during the second quarter of 2002. Based upon the results of this test, the Company determined that there was no impairment of goodwill or indefinite lived intangible assets regarding its Pharmacy Care segment, but a potential impairment of goodwill or indefinite lived intangible assets may exist relative to its other two subsidiaries, Physical Therapy & Rehabilitation and CyberCare Technology as of January 1, 2002. The amount of the potential impairment was estimated at 5,394,000 as a result of the transitional impairment test.

During the quarter ended September 30, 2002, the Company noted additional indicators of impairment in its Pharmacy Care and Physical Therapy & Rehabilitation segments. In particular, the Company experienced a significant decline in the operations of these two segments during the third quarter of 2002. As a result, the Company finalized its transitional impairment test and also performed an updated valuation of its intangible assets at September 30, 2002 to determine whether any additional

8

impairment had occurred. As a result of these analyses, the Company determined that its intangible assets were impaired by \$6.5 million at September 30, 2002. Of this amount, approximately \$4.0 million was impaired as of January 1, 2002 and the remainder had become impaired subsequent to that date. The \$3.98 million impairment that existed at January 1, 2002 was recorded as the cumulative effect of change in accounting principle as the result of adopting SFAS 142. The remaining \$2.5 million was recorded in operations as an impairment of long-lived assets during the quarter ended September 30, 2002.

Recent Accounting Pronouncements

In August 2001, the FASB issued Statement No. 144, ACCOUNTING FOR THE IMPAIRMENT OR DISPOSAL OF LONG-LIVED ASSETS, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets and supercedes FASB Statement No. 121, ACCOUNTING FOR THE IMPAIRMENT OF LONG-LIVED ASSETS AND FOR LONG-LIVED ASSETS TO BE DISPOSED OF, and the accounting and reporting provisions of Accounting Principles Board (APB) Opinion No. 30, REPORTING THE RESULTS OF OPERATIONS- REPORTING THE EFFECTS OF DISPOSAL OF A SEGMENT OF A BUSINESS AND EXTRAORDINARY, UNUSUAL AND INFREQUENTLY OCCURRING EVENTS AND TRANSACTIONS. The Company adopted the provisions of FASB Statement No. 144 as of January 1, 2002.

Note - 2 Goodwill and Identifiable Intangible Assets

Intangible Assets and the related accumulated amortization, in thousands, and amortization periods are set forth below:

| September 30, 2002 | | | |
|-----------------------------|--------------------|--------------------|---------------|
| SEPTEMBER 30, 2002 DECEMBER | 31, 2001 | AMORTIZATION PE | RIODS (YEARS) |
| | | | |
| Licenses | \$ 10 , 937 | \$ 12 , 906 | 10 |

| Accumulated Amortization | (3,881) | (2,914) | |
|----------------------------------|-----------------|----------|----------|
| Licenses, net | \$ 7,056 | \$ 9,992 | |
| GoodwillAccumulated Amortization | \$ 616 (593) | \$ 5,746 | (661) |
| Goodwill, Net | \$ | 23 | \$ 5,085 |

The following reconciliation adjusts net loss for amortization expense related to goodwill that is no longer amortized under the provisions of SFAS No. 142:

| | Three Months Ended SEPTEMBER 30, 2001 | |
|--|---------------------------------------|---------------------|
| (Unaudited, amounts in thousands, except per share data) | | |
| Net loss Goodwill amortization, net of tax | \$ (8,299) 70 | \$(21,228) 208 |
| Adjusted net loss | \$ (8,229) ======= | \$(21,020) |
| Basic and diluted net loss per share: | | |
| 9 | | |
| Net loss Goodwill amortization | \$ (0.13) .00 | \$ (0.33) .00 |
| Adjusted net loss | \$ (0.13) | \$ (0.33) ====== |
| Basic and diluted weighted average shares outstanding | 65,824 | 65 , 178 |

Note 3 - Senior Secured Convertible Notes

In March 2002, the Company entered into a term sheet with an investor (the "Lender") whereby the Company may borrow up to \$5,000,000 in exchange for senior convertible promissory note(s) (the "Convertible Notes"). The Convertible Notes have a 12-month term and requires interest at 10% per annum, increasing to 15% retroactively upon default. At the election of the Lender, both principal and interest are convertible into the Company's common stock at 85% of the closing bid price on the day prior to conversion, but in no event less than \$0.30 per share or more than \$1.25 per share. The adjusted conversion price (calculated as proceeds received less the value allocated to the warrants and to the fees divided by the \$0.30) was less than then trading price of the stock on the commitment date or date of funding. As a result the company recorded a beneficial conversion feature that is being accreted through interest expense over the one year life of the underlying debenture. Beneficial conversion

calculated for the underlying debenture was \$88,000, with the beneficial conversion accreted for 2002 amounting to \$46,000 for the nine months ended September 30, 2002. The notes are secured by the Accounts Receivable of CyberCare, a second position on the accounts receivable of the Physical Therapy subsidiary, subject to the consent of the subsidiary's existing lender, the furniture, fixtures and equipment of CyberCare and the Physical Therapy Subsidiary, subject to any existing encumbrances, inventory of CyberCare, and the proceeds and collateral securing such proceeds of the October 31, 2000 Promissory Note from Outreach Programs, Inc. The Company issued warrants to purchase 250,000 shares of common stock at \$0.75 per share, exercisable within 24 months for each \$2,500,000 funded by the Lender. As of September 30, 2002, the warrants were valued at \$78,000 using the Black-Scholes valuation method. The warrants are being accreted through interest expense over the one year life of the underlying debentures. The Company is also liable for a commission (payable in cash and warrants) and the Lender's legal fees in connection with review of the transactional documents and closing of the transaction. All of the underlying shares, whether through conversion of the Convertible Notes or exercise of the warrants, have registration rights. As of May 8, 2002, the Company had issued the Convertible Notes for the entire \$5,000,000 under this commitment as described in the following three paragraphs.

The Company received \$900,000 (less fees of \$100,000) for working capital purposes and issued a \$1,000,000 60-day promissory note dated January 22, 2002 to Dynamic Holdings Corporation and its principal (the "Note"). The Note was due on March 22, 2002 and interest was due on the unpaid principal balance at the rate of 8% per annum. The Company refinanced the Note without penalty by issuing a \$1,250,000 convertible promissory note dated April 5, 2002 ("Dynamic Note"), which is part of the \$5,000,000 commitment discussed above. The Dynamic Note is secured, by the outstanding balance of that certain \$3,225,000 promissory note dated October 31, 2000, given by Outreach Programs, Inc. to the Company in exchange for the sale of 100% of the stock in Carolina Rehab, Inc.

The Company received \$228,000 (less fees of \$2,000) for working capital purposes and issued a \$230,000 10-day promissory note dated February 25, 2002 to Dynamic Holdings Corporation. Interest on the unpaid principal balance accrues at the rate of 8% per annum. This note was satisfied through an offset against amounts borrowed under a \$1,250,000 convertible promissory note issued to Manford Investments, LLC (an affiliate of Dynamic Holdings and C.C. Fortune Ventures, LLC) dated April 4, 2002 (the "Manford Note"). The Manford Note is part of the \$5,000,000 commitment discussed above.

10

The Company received \$2,500,000 (less fees of \$150,000) for working capital purposes and issued a \$2,500,000 senior convertible promissory note to C.C. Fortune Venture, LLC dated March 7, 2002, which is part of the \$5,000,000 commitment discussed above.

On June 2, 2002, the Company issued a \$500,000 one-year Senior Secured Convertible Note to Manford Investments LLC. At the election of Manford, both the principal and interest are convertible into the Company's common stock at 85% of the closing bid price on the day prior to conversion, but in no event less than \$0.20 per share or more than \$0.75 per share. The adjusted conversion price (calculated as proceeds received less the value allocated to the warrants and to the fees divided by the \$0.20) was less than then trading price of the stock on the commitment date or date of funding. As a result the company recorded a beneficial conversion feature that is being accreted through interest expense over the one year life of the underlying debenture. Beneficial conversion accreted for 2002 amounting to \$4,000 for the nine months ended September 30, 2002. The Company issued warrants to purchase 90,000 shares

of common stock at \$0.75 per share, exercisable within 24 months. As of September 30, 2002, the warrants were valued at \$6,000 using the Black-Scholes valuation method. The warrants are being accreted through interest expense over the one year life of the underlying debentures

On August 14, 2002, the Company issued a \$2,000,000 two year Senior Secured Convertible Note to C.C. Fortune Venture, LLC. The convertible note requires interest at 10% per annum, increasing to 15% retroactively upon default. At the election of the lender, both principal and interest is convertible into shares of the Company's common stock at \$0.10 per share. The adjusted conversion price (calculated as proceeds received less the value allocated to the warrants and to the fees divided by the \$0.10) was less than then trading price of the stock on the commitment date or date of funding. As a result the company recorded a beneficial conversion feature that is being accreted through interest expense over the two year life of the underlying debenture. Beneficial conversion calculated for the underlying debenture was \$201,520. The note is secured by 100% of the issued and outstanding shares of stock of CyberCare Technologies, Inc. All of the underlying shares, whether through conversion of the Convertible Note or exercise of the warrants, have registration rights. The Company also issued warrants, the warrants were valued at \$27,200 using the Black-Scholes valuation method to purchase 400,000 shares of common stock at \$0.20 per share, and are exercisable for a period of 36 months from the date of grant. The warrants are being accreted through interest expense over the two year life of the underlying debentures. The Company is also liable for a commission (payable in cash, \$120,000 and warrants) and the Lender's legal fees in connection with review of the transactional documents and closing of the transaction. As of October 8, 2002, the Company had issued the Convertible Notes for the entire \$2,000,000.

Currently the Company is in default of its Senior Secured debentures for non payment of interest. Also, the company is in default with its Physical Therapy and Rehabilitation lender for falling below its allowable eligible assets. At this time neither of the debt holders have called the note agreements and they are working with the company to rectify the defaults in a beneficial manner for both the company and the holders of the notes.

Note 4 - Inventories

Inventories are stated at the lower of cost or market. Cost is determined using the first-in, first-out method. Finished goods and work-in-process inventories include material, labor and manufacturing overhead costs. Inventories consist of the following:

| | September 30, 2002 | December 31, 2001 |
|-----------------|--------------------|-------------------------|
| | | |
| Component parts | \$ 1,893,000 | \$ 1,616,000 |
| Work-in-process | 29,000 | 29,000 |
| Finished goods | 1,168,000* | 954,000 |
| | | |
| | 11 | |
| | \$ 3,090,000 | \$ 2,599,000 ======= |

* Included in finished goods as of September 30, 2002 is \$480,000 of inventory that has been shipped to Syzex and is the subject of certain litigation. It is the company's' position that the inventory was properly sold to Syzex and we are demanding full payment of the sale as part of the

litigation. Inventory adjusted for the Syzex owned inventory is \$2,610,000, with finished goods inventory of \$688,000.

Note 5 - Dispositions and Discontinued Operations

DISCONTINUED OPERATIONS

Prior to January 1, 2002, the Company accounted for discontinued operations accordance with APB Opinion No. 30: REPORTING THE RESULTS OF in OPERATIONS--REPORTING THE EFFECTS OF DISPOSAL OF A SEGMENT OF A BUSINESS, AND EXTRAORDINARY, UNUSUAL AND INFREQUENTLY OCCURRING EVENTS AND TRANSACTIONS, which required that the disposal of a segment be treated as a discontinued operation upon meeting certain criteria, including management agreeing to and commencing with a formal plan to dispose of a segment. As discussed in Note 1, the Company adopted SFAS No. 142 on January 1, 2002. SFAS No. 142 permits discontinued operations treatment for components of a segment and expands the types of transactions that require discontinued operations treatment. Thus, disposal transactions that were commenced prior to January 1, 2002 have been accounted for under APB No. 30 while disposals that occurred during 2002 have been accounted for under SFAS No. 144. SFAS No. 144 also requires that discontinued operations that were treated as such prior to adopting SFAS No. 144 continue to be accounted for under APB No. 30 until such time as discontinued operations accounting treatment is no longer required.

Effective December 3, 2001, the Company and the operating subsidiaries comprising its air ambulance business ("Air") entered into a transaction with Aim Aircraft ("Aim") in which Aim assumed the office/hangar leases, purchased the existing furniture, fixtures and equipment (except aircraft) and acquired the corporate telephone numbers, corporate names, employees and a Federal Aviation Administration (`FAA") 135 Certificate. The Company retained ownership of the aircraft and remains liable for approximately \$13,700,000 of the aircraft financing. As part of the transaction, Aim leased certain of these aircraft.

On December 17, 2001, the Company received an independent appraisal on the leased airplanes. At that date, the average market value of all the planes was \$13,576,000 with a suggested sale price of \$13,832,000.

Due to the Company's financial situation, the Company was unable to expend resources to maintain the aircraft in accordance with the lease agreement with Aim and fund the required debt service. The Company was notified by the aircraft lender that the Company was in violation of the loan agreements. The company has voluntarily surrendered the aircraft to the lender. As of September 30, 2002, the Company had \$1,268,000 accrued for the estimated future operating losses of Air. Based on this information and a proposal made by the Company to Textron (the lender) as full satisfaction, the Company at this time does not believe an additional reserve is needed for the payment of the leases at this time. Textron has begun the process of selling the aircraft, thus reducing the debt obligation of the company. At present, Textron was unable to provide the company a final figure for the required deficiency. The company has made a proposal to Textron in full satisfaction of any deficiency amount. This proposal is being considered by Textron.

For financial accounting purposes, a sale will not be recognized until the Company sells the aircraft and/or is removed from the related debt guarantees. Accordingly, until such event occurs, the operations of the air ambulance segment will be accounted for as discontinued operations in accordance with APB No. 30.

During the quarter ended September 30, 2002, the Company ceased operations at approximately 30 of its Physical Therapy and Rehabilitation locations. Such closures have been treated as discontinued operations under SFAS No. 144 and, accordingly, the revenues and expenses of such locations have been reclassified to discontinued operations for all periods presented in the accompanying condensed consolidated statements of operations. The assets of these locations primarily consisted of assets leased under operating leases and thus required no reclassification of assets or liabilities of discontinued operations at September 30, 2002. The Company does not expect the resulting loss from the disposal of these locations to be material to its financial position or results of operations.

DISPOSITIONS

Physician Practice - Effective January 26, 2001, the Company sold certain assets and related liabilities of its physician practice to a related party in exchange for the return of 140,000 common shares of the Company owned by the related party valued at \$691,000. The Company recognized a gain in the amount of \$92,000 on this transaction.

Southeast Acquisition and Disposition - The Company originally acquired 100% of the outstanding common stock of Southeast Medical Centers, Inc. ("Southeast") effective August 1, 1999. Effective January 7, 2002, the Company entered into a comprehensive settlement agreement (the "Southeast Agreement") involving the transfer of Southeast to Southeast's former owners. Under the Southeast Agreement, the Company transferred 100% of the stock of Southeast and received a \$281,000 note which bears interest at 8.0% and is payable over three years. The note is collateralized by the stock of Southeast. The Southeast Agreement also calls for the waiver of any contingent consideration that would have been due under the terms of the original purchase agreement between the Company and former owners. The Company recognized a loss on the sale of this subsidiary of approximately \$514,000 from this transaction during the first quarter of 2002.

Sleep Disorder Center - As part of a settlement of certain litigation, effective May 1, 2002, the Company transferred all of the assets of Tallahassee Sleep Disorder Center to its original owner for no consideration. The Company recognized a loss on the transfer of this subsidiary of approximately \$239,000 from this transaction during the second quarter of 2002.

The following unaudited pro forma financial data is presented to illustrate the estimated effects on the condensed consolidated results of operations as if the Company's dispositions had occurred as of the beginning of each calendar year presented after giving effect to certain adjustments, including amortization of goodwill and related income tax effects. The pro forma financial information does not purport to be indicative of the results of operations that would have occurred had the transactions taken place at the beginning of the periods presented or of future results of operations.

| | Nine months ended September 2002 2001 | | |
|---|--|----------------|--|
| Revenue | \$ 11,998,000 | \$ 12,682,000 | |
| Net loss | \$(22,359,000) | \$(18,366,000) | |
| Net loss per common share (basic and diluted) | \$ (0.31) | \$ (0.28) | |

Note 6 - Litigation and Contingencies

Litigation - The Company is engaged in litigation with various parties regarding matters of dispute that have arisen in the normal course of business. The Company is currently unable to predict the financial impact of litigation at this time.

The Company has previously disclosed the 14 purported class action lawsuits that were filed against CyberCare and certain of its executive officers alleging violations of federal securities laws. These lawsuits were consolidated into a single class action lawsuit by the United States District Court for the

13

Southern District of Florida on November 4, 2000. The Consolidated Amended Complaint ("Complaint") principally alleges that the Company and certain of its officers and directors made misrepresentations or omissions regarding the development and future sales forecasts of its Electronic HouseCall(R) system products and revenues of its pharmacy division. On April 19, 2002, counsel for the parties entered into a Memorandum of Understanding addressing the terms of a settlement (the "Settlement"). The Settlement involves the payment of \$3.1 million, to be provided under an insurance policy, and the issuance by the Company of 5,000,000 shares of stock (subject to certain sale restrictions), without any admission of liability by the Company. The Settlement is subject to definitive settlement documents and approval by the court. As of September 30, 2002, the Company had issued the 5,000,000 shares of common stock.

Our Physical Therapy and Rehabilitation subsidiary ("PT&R") received a letter from the Center for Medicare and Medicaid Services ("CMS") and its intermediary in April 2001 notifying it of the suspension of Medicare payments. CMS alleged that certain patient complaints, which constituted less than 1% of PT&R's Medicare patients, and other alleged regulatory non-compliance, justified the payment suspension. During the suspension, the Medicare program continued to process PT&R's claims, but held payment in escrow. In August 2001, the suspension was lifted and payment for processed claims was released although approximately \$1,115,000 remained held in escrow, pending further review. CMS completed its review and issued its formal determination in April 2002. CMS determined that approximately \$1,300,000 of overpayments were made. PT&R disputes the overpayment and has an appeal hearing set for the week of February 11, 2003. As of September 30, 2002, the Company has recorded an allowance for the entire overpayment.

A complaint was filed against the Company on August 13, 2001, alleging that the Company breached certain obligations in connection with the removal of a restrictive legend from stock issued to the plaintiff. Mediation was held in March 2002, which resulted in settlement of the dispute. Pursuant to the settlement, the Company issued and registered 869,566 shares of common stock, transferred the assets of the Sleep Disorder Center (previously owned by the plaintiff) back to the plaintiff, and made a cash payment, which the Company's insurance carrier covered, in the amount of \$200,000.

A complaint was filed against the Company by IMRglobal (n/k/a CGI Information Technology Services) on November 21, 2001 in the 6th Judicial Circuit in and for Pinellas County, Florida, alleging that the Company breached its obligations to make payment for software development services of \$1,113,000. A settlement was reached and the Company paid \$150,000 and issued 500,000 shares of its common stock to the plaintiff. The shares were registered, and are subject to certain sale restrictions.

In February 2002, an arbitration panel determined that the Company is

responsible for damages and attorneys' fees in connection with the Company's performance under an option agreement. From inception, the Company believed there was no merit to the claim and damages, if any, were covered under an insurance policy. The insurer later asserted that an exclusion from coverage applied. As part of the settlement reached at the mediation of the class action litigation, the Company waived its claim against the insurer for the coverage denial. On April 29, 2002, an Award of Arbitrators was issued and on June 17, 2002, a final judgment was issued for \$1,114,000 plus interest, of which the entire amount was reserved as of September 30, 2002.

A complaint was filed against the Company by Health Hero Network, Inc. on May 31, 2002 in the Superior Court of California in and for the County of Santa Clara, alleging that the Company breached its obligations to make payments for product development services of \$450,000 and seeking additional damages of \$3,388,750. The Complaint was served on July 25, 2002 and a separate demand for arbitration, with the American Arbitration Association, was served on the Company on July 24, 2002. The Company is investigating this matter and will respond to the complaint and demand for arbitration after such investigation is complete. The Company believes the claims lack merit and intends to vigorously defend this suit, and counter sue Health Hero Network Inc

The Company is in litigation with a previous employee based upon termination of the employee's employment contract. The Company has accrued its best estimate as of September 30, 2002 for this liability.

14

Contingencies - The Nasdaq Stock Market, Inc. ("Nasdaq") notified the Company that on February 20, 2002, the price of the Company's common stock had closed for the previous 30 consecutive trading days below the minimum \$1.00 per share requirement under its Marketplace Rules. In May 2002, the Company transferred its common stock listing to the Nasdaq SmallCap Market, which provided an extended grace period in which to satisfy the listing requirements for the Company's securities. The Company had until August 19, 2002 to regain compliance under the Nasdaq Marketplace Rules.

On August 2, 2002, Nasdaq responded to an inquiry by the Company regarding a deficiency in outside directors supporting the Company's Audit Committee activities. Nasdaq agreed with the Company's assertion that it was not in compliance with the audit committee requirements of NASDAQ and needed to remedy the situation. The Director issue was due on August 16, 2002, but was combined as one requirement by Nasdaq and the Company has until August 19, 2002 to respond. The Company has subsequently added outside directors after the NASDAQ deadline.

On October 31, 2002 the Company received notice that it would be delisted from the NASDAQ Small cap market. On November 1, 2002, the Company's common stock was delisted from trading, on the NASDAQ stock market. The Company's common stock is currently trading on the NASD over the counter bulletin board. On October 31, 2002 the Company advised NASDAQ of its intention to appeal the delisting decision.

Note 7 - Related Party Transactions

During the second quarter of 2002, the Chief Executive Officer and President of the Company loaned the Company \$250,000 for working capital purposes. The loans bore interest at 8%. The loans were secured by the accounts receivable of the Pharmacy business. As of September 30, 2002, the Company has repaid the amounts in full.

Note 8 - Note Payable

On June 26, 2002, the Company received \$125,000 from Manford Investments LLC under a promissory note, which bears interest at 8% per year for working capital purposes. The term was for 30 days, however, the note remained outstanding at November 19, 2002. The note is included in the current portion of notes payable and long-term debt as of September 30, 2002.

On October 21, 2002, the Company received \$95,000 from Manford Investments LLC under a promissory note, which bears interest at 8% per year for working capital purposes. The term was for 30 days, and was repaid on November 1, 2002.

On October 30, 2002, the Company received \$39,500 from Manford Investments LLC under a promissory note, which bears interest at 8% per year for working capital purposes. The term was for 30 days, and was repaid on November 1, 2002.

On November 14, 2002, the Company received \$50,000 from CC Fortune Venture LLC under a \$230,000 promissory note, which bears interest at 8% per year for working capital purposes. The term is for 30 days.

Note 9 - Changes in Stockholders' Equity

During the three months ended September 30, 2002, the Company issued:

.. 10,056 shares of common stock, valued at \$1,400, which was purchased under the Company's Employee Stock Purchase Plan,

15

- .. 35,000 shares of common stock, valued at \$4,200, in settlement of a severance dispute,
- .. 178,571 shares of common stock, valued at \$25,000, in settlement of certain accounts payable.

Note 10 - Operating Segments

The Company has organized and determines its segments based on market segment operating groups. Each group reports its results of operations and makes requests for capital expenditures to the individual management of the segment, the Chief Accounting Officer, the Corporate Executive Vice President and the Chief Executive Officer. Under this organizational structure, the Company's operating groups have been aggregated into three reportable operating segments: physical therapy and rehabilitation services, pharmacy services (collectively "Services") and technology.

The other category presented below includes the corporate office and elimination of inter-company activities, neither of which meet the requirements of being classified as an operating segment. As discussed in Note 5, the Company entered into an agreement to sell Air during September 2001. Accordingly, Air is not separately presented below for either September 30, 2002 or 2001, but rather is included as part of the Other category because the Company is accounting for this disposition as a discontinued operation.

The Company evaluates the performance of its reportable operating segments based primarily on net sales, net loss and working capital (deficit). Segment information for the three and nine months ended September 30, 2002 and 2001 is as follows:

| For the three months ENDED SEPTEMBER 30, 2002 | - | Physical Thera and REHABILITAT | PHARMACY | T(| OTAL SERVICES | | TECHNOLOGY |
|--|----|--------------------------------------|-----------------|----|---------------|----|-------------|
| Net revenues Loss from continuing | \$ | 1,085,000 | \$ 1,034,000 | \$ | 2,119,000 | Ş | 55,000 |
| operations | | (3,725,000) | (1,404,000) | | (6,450,000) | | (2,249,000) |
| Total assets | \$ | 3,486,000 | \$ 1,847,000 | \$ | 5,333,000 | \$ | |

| For the three months ENDED SEPTEMBER 30, 2001 | | Physical Then and REHABILITATI | | PHARMACY | TOTAL SERVICES | TECHNOLOGY |
|--|----|--------------------------------------|----|------------------------|------------------------------|---------------------------|
| Net revenues | \$ | 1,302,000 | \$ | 1,586,000 | \$ 2,888,000 | \$ 1,030,000 |
| Income (loss) from continuing operations | | | | (00.0.000) | (000,000) | (2.705.000) |
| Total assets | \$ | (66,000) 6,501,000 | | (226,000) 2,361,000 | \$ (292,000) 8,862,000 | (3,725,000) 20,921,000 |
| For the nine months ENDED SEPTEMBER 30, 2002 | | | | | | |
| Net revenues | \$ | 3,625,000 | \$ | 4,826,000 | \$ 8,451,000 | \$ 554,000 |
| Loss from continuing operations | Ş | (3,198,000) | Ş | (1,748,000) | \$ (4,946,000) | \$ (6,080,000) |
| For the nine months ENDED SEPTEMBER 30, 2001 | | | | | | |
| Net revenues | \$ | 4,307,000 | \$ | 4,606,000 | \$ 8,913,000 | \$ 1,646,000 |
| Income (loss) from continuing operations | \$ | (146,000) | \$ | (444,000) | \$ (590,000) | \$ (13,540,000) |

Note 11 - Subsequent Events

16

On October 31, 2002 the Company received notice that it would be delisted

from the NASDAQ Small cap market. On November 1, 2002, the Company's common stock was delisted from trading, on the NASDAQ stock market. The Company's common stock is currently trading on the NASD over the counter bulletin board. On October 31, 2002 the Company advised NASDAQ of its intention to appeal the delisting decision.

A forbearance agreement was entered into with Healthcare Business Credit Corporation, the lender for the Physical Therapy segment, whereby the lender will split accounts receivable collections made to pay down the line of credit and advance those amounts to the Physical Therapy segment.

17

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "could," "may," "will," "believes," "anticipates," "plans," "expects," "projects," "estimates," "intends," "continues," "seeks," "predicts," "expectations," variations of such words and similar expressions are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions ("Future Factors") that are difficult to predict. As a result, because these statements are based on expectations as to future performance and events and are not statements of fact, actual events or results may differ materially from those expressed or forecast in such forward-looking statements. Factors that might cause the Company's actual results to differ materially from those indicated by such forward-looking statements include, without limitation, those discussed in our filings with the Securities and Exchange Commission, including, but not limited to, our most recent proxy statement and "Risk Factors" in our most recent Form 10-K, as well as Future Factors that may have the effect of reducing our available operating income and cash balances.

Future Factors include risks associated with the uncertainty of future financial results; government approval processes; changes in the regulation of the healthcare and technology industries at either the federal or state levels; changes in reimbursement for services by government or private payers; competitive pressures in the healthcare and technology industries and the Company's response thereto; delays or inefficiencies in the introduction, acceptance or effectiveness of new products; the impact of competitive products or pricing; the Company's relationships with customers and partners; cash expenditures related to possible future acquisitions and expansions; on-going capital expenditures; the Company's ability to obtain capital on favorable terms and conditions; increasing prices of products and services; U.S. and non-U.S. competitors, including new entrants; rapid technological developments and changes and the Company's ability to continue to introduce competitive new products and services on a timely, cost-effective basis; the mix of products and services; the availability of manufacturing capacity, components and materials; the ability to recruit and retain talent; the achievement of lower costs and expenses; credit concerns in the emerging service provider market; customer

demand for the Company's products and services; U.S. and non-U.S. government and public policy changes that may affect the level of new investments and purchases made by customers; changes in U.S. and non-U.S. governmental regulations; protection and validity of patent and other intellectual property rights; reliance on large customers and significant suppliers; the ability to supply customer financing; technological implementation; cost/financial risks in the use of large, multiyear contracts; the Company's credit ratings; the outcome of pending and future litigation; continued availability of financing, financial instruments and financial resources in the amounts, at the times and on the terms required to support the Company's future business; general industry and market conditions and growth rates; and general U.S. and non-U.S. economic conditions, including interest rate and currency exchange rate fluctuations.

You should not unduly rely on such forward-looking statements when evaluating the information presented herein. These statements should be considered only after carefully reading this entire Form 10-Q and the documents incorporated herein by reference.

The following discussion and analysis addresses the Company's results of operations and financial condition and should be read in conjunction with the Company's condensed consolidated unaudited Financial Statements and Notes thereto appearing in Part I, Item 1 in this Form 10-Q, and the Company's audited Consolidated Financial Statements listed in Part II, Item 7 and the Notes thereto appearing in the Company's 2001 Annual Report on Form 10-K.

COMPARISON OF THE RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2002 and 2001 $\,$

18

The following table represents the sales for each segment and its related cost of services for the periods indicated:

| | For the Three ENDED SEPTEN | | | For the Three Months ENDED SEPTEMBER 30 | | | |
|--------------------------|-------------------------------|-------------|----------|--|-----------------------|--|--|
| | 2002 Net | | % CHANGE | | 2001 Costs of | | |
| | REVENUE | REVENUE | | SERVICES | SERVICE | | |
| Physical Therapy and | | | | | | | |
| Rehabilitation Services | \$1,085,000 | \$1,302,000 | (16.67) | \$ 684,000 | \$ 501,000 | | |
| Pharmacy Services | 1,034,000 | 1,586,000 | (34.74) | 993,000 | 1,408,000 | | |
| Total Service Businesses | 2,119,000 | 2,888,000 | (26.59) | 1,677,000 | 1,909,000 | | |
| Technology | 55,000 | 1,030,000 | (94.7) | 286,000 | 747,000 | | |
| Total | \$2,515,000 ======= | \$3,918,000 | (35.8) | \$1,963,000 ====== | \$2,656,000 ====== | | |

NET REVENUES

Net revenues for the three months ended September 30, 2002 decreased by approximately 35.8% when compared to the three months ended September 30, 2001. The net revenue decrease was a result of a decrease in the physical therapy and rehabilitation services segment (PT&R) of approximately \$217,000, a decrease in the pharmacy services segment of \$551,000, and a decrease in the technology segment of approximately \$976,000, of which \$247,000 was generated within the Sleep disorder center which is not part of the technology business in the third quarter of 2002.

The decrease in the Physical Therapy & Rehabilitation Services excluding the physician practice and chiropractic practice which were sold in January 2001 and January 2002 respectively, had a decrease in revenue of \$18,000 for the three months ended September 30, 2002 over the same period last year. The decrease was due to loss of business due to capital shortages, and an effort to close unprofitable clinics. As a result, the segment closed approximately 30 clinics during the three month period, and is concentrating its growth efforts on its existing clinics by initially focusing on operational earnings rather than top line revenues. The closed clinics have been accounted for as discontinued operations in accordance with SFAS no,. 144. Once these clinics and the corporate overhead are operationally secure with proper cost management in place, focus will again return to growing profitable revenue at these and other clinics.

Due to the sale of the chiropractic practice, which is part of PT&R, on January 7, 2002, no revenue is reflected in the 2002 financial statements, but for the three months ended September 30, 2001, the practice generated approximately \$199,000 of revenue.

The decrease in the Pharmacy services segment is a direct result of a loss of approximately 60 facilities due to, activities which occurred after the dismissal of the unit President and the improper interpretation of what was disclosed in the Company's August 13, 2002 8-K filing. The segment is currently operating and servicing approximately 15 facilities and is in the process of expanding with the recent hiring of a sales/marketing professional and new Pharmacist/General Manager. The company has been acting under the advice being provided by legal counsel specifically with regard to options that the company may have resulting from activities of former employees and possibly pharmacy competitors. The company plans to aggressively pursue all legal remedies in order to protect the company and its' shareholders. As a result of the Company's investigation surrounding the dismissal of the President of the Pharmacy services segment and the resulting loss of business, an employee alleged that this segment

19

was recycling drugs and not following drug disposal procedures. The Company is in the process of utilizing outside counsel to investigate this situation, but at this time cannot conclude as to whether any liability or exposure exists regarding this matter.

The technology segment revenue (EHC related revenue), excluding the Company's Sleep Disorder Center which was transferred in May 2002 to its previous owner, decreased by approximately \$729,000. Revenue of \$450,000 from one customer booked in the third quarter of 2001 was reversed in the 4th quarter of 2001.; therefore, the net decrease in revenue was \$279,000.

The Sleep Disorder Center generated \$247,000 of revenue during the three months ended September 30, 2001.

COST OF SERVICES

Costs of services for the three months ended September 30, 2002 decreased by approximately 26.1%, \$693,000, when compared to the three months ended September 30, 2001. The cost of services decrease was a result of an increase in the physical therapy and rehabilitation services segment of approximately \$183,000, a decrease in the pharmacy services segment of \$415,000 and a decrease in the technology segment of approximately \$1,106,000.

The increase in cost of services relating to the physical therapy and rehabilitation services segment are related to the cost of payroll paid during the three months ended September 30, 2002 for the closed clinics. The decrease in cost of services for the Pharmacy services segment is representative of the decreases in revenue for such segments. There were decreases in overall operating costs which are directly consistent with the corresponding decreases in revenue for such segments. There were decreases in direct operating costs such as salaries, rent, insurances and supplies due to the closing of operating locations.

The cost of services for the technology segment for the three months ended September 30, 2002 decreased by approximately 61.7% as compared to the same period last year. The decrease was a direct result of the previously mentioned revenues generated in 2001 with an approximate cost of \$450,000 as well as the ongoing concerted effort of the company to reduce its operating costs. Such costs reductions included the reduction of payroll related costs of approximately of \$450,000, an increase in network services of \$98,000, and a reduction of telephone related services of \$170,000. During the three months ended September 30, 2001, \$646,000 of costs classified as costs of services, which were related to product development and technology were allocated to Research and Development. This allocation was consistent with prior quarters.

SELLING, GENERAL AND ADMINISTRATIVE

Selling, general and administrative expense for the three months ended September 30, 2002 decreased by 48.4% as compared to the three months ended September 30, 2001 primarily due to the reduction in payroll related costs of \$1,080,000, and a reduction in professional fees and contract services of \$1,672,000. During the three months ended September 30, 2001, certain costs amounting to approximately \$922,000 were allocated to research and development for the technology entity, which was consistent with previous quarters reporting. These costs were related to product development and technology. The increase, relative to the prior year allocation, was offset by decreases in payroll, contract labor and professional fees. The Company is taking further steps to reduce costs and will continue to monitor all expenditures.

RESEARCH AND DEVELOPMENT

Research and development expenses for the three months ended September 30, 2002 decreased by approximately \$2,087,000 or 83.1% when compared to the same period last year. The decrease was due to the allocation of certain Cost of Services and Selling, General and Administrative costs in 2001 to

20

Research and Development relating to the development of new products. These costs amounted to approximately \$1,568,000 for the three months ended September

30, 2001. New methodology and approaches instituted in the later half of 2001 and continued through 2002 continue to generate improved research and development efforts with significant reductions in spending.

DEPRECIATION AND AMORTIZATION

Depreciation and amortization decreased, in total, during the three months ended September 30, 2002 by \$105,000 as compared to the same period last year. Amortization as a result of adapting SFAS 142, which no longer requires goodwill to be amortized, decreased \$70,000. However, when the impairment valuation for SFAS 142 was performed an operational impairment of \$1,640,000 was recorded for the PT&R segment and an \$885,000 impairment was recorded for the Pharmacy segment for the three months ended September 30, 2002.

OTHER INCOME (EXPENSE)

During the three months ended September 30, 2002, interest income decreased to \$150,000 compared to \$263,000 for the three months ended September 30, 2001, due to a decrease in available cash for investment purposes.

During the three months ended September 30, 2002, interest expense increased to \$655,000 compared with \$515,000 for the three months ended September 30, 2001, primarily due to the Company's issuance of the additional \$5,000,000 in senior secured convertible notes and convertible subordinated debentures required to fund the ongoing operations of the Company in March and April 2002.

During the three months ended September 30, 2002, amortization of beneficial conversion feature and discount increased to \$293,000 compared with \$215,000 for the three months ended September 30, 2001 primarily due to the Company's issuance of the senior secured convertible notes in 2002 of \$7,500,000.

COMPARISON OF THE RESULTS OF OPERATIONS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2002 AND 2001

| | - | PTEMBER 30 | | | ine Months EPTEMBER 30 |
|---------------------------|--------------|--------------|----------|------------------|---------------------------|
| | 2002 Net | 2001 Net | % CHANGE | 2002 Costs of | 2 2 Cos |
| | REVENUE | REVENUE | | SERVICES | SERV |
| Physical Therapy and | | | | | |
| Rehabilitation Services | \$ 3,625,000 | \$ 4,307,000 | (15.83) | \$ 1,688,000 | \$ 1,930, |
| Pharmacy Services | 4,826,000 | 4,606,000 | 4.8 | 4,156,000 | 3,846, |
| Total Services Businesses | 8,451,000 | 8,913,000 | (5.2) | 5,844,000 | 5,776, |
| Technology | 554,000 | 1,646,000 | (66.3) | 1,480,000 | 1,746, |

| | | | ===== | | |
|-------|--------------|--------------|--------|--------------|-----------|
| Total | \$ 9,005,000 | \$10,559,000 | (14.7) | \$ 7,324,000 | \$ 7,522, |

NET REVENUE

Net revenue for the nine months ended September 30, 2002 decreased by approximately 14.7% when compared to the nine months ended September 30, 2001. The decrease was a result of a decrease in the physical therapy and rehabilitation services segment of approximately \$682,000. However, The

21

physical therapy and rehabilitation services segment, excluding the physician practice and chiropractic practice, increased approximately \$102,000 for the nine months ended September 30, 2002. and an increase in the pharmacy services segment of \$220,000, and a decrease in the technology segment of approximately \$1,092,000.

In addition to the closing of a number of unprofitable clinics and a lack of support from our medical directors due to lack of cash availability, the closed clinics have been accounted for as discontinued operations in accordance with SFAS no. 144. The decrease in revenue during the nine months ended September 30, 2002 as compared to 2001 for the physical therapy and rehabilitation segment was also due to the sale of the physician practice (January 2001) and chiropractic center (January 2002) which generated total revenue of approximately \$784,000 for the nine months ended September 30, 2001.

The increase in revenue from our pharmacy services segment resulted from an increase in services and the expansion of the customer base during the first two quarters of 2002.

The technology segment, excluding the Sleep Disorder Center, had a decrease in revenue of \$815,000, which included a customer order which was subsequently reversed in the fourth quarter of 2002 of \$450,000, for a net decrease in revenue of \$365,000.

The Sleep Disorder Center had a decrease in revenue of approximately \$277,000 because the current year's revenue was only generated during a portion of the nine-month period ended September 30, 2002 compared to the full nine-month period in 2001.

COST OF SERVICES

Cost of services for the nine months ended September 30, 2002 decreased by approximately \$198,000 when compared to the nine months ended September 30, 2001. The cost of services decrease was a result of a decrease in the physical therapy and rehabilitation services segment of approximately \$242,000, an increase in the pharmacy services segment of \$310,000 and a decrease in the technology segment of approximately \$267,000.

The physical therapy and rehabilitation services segment, excluding the cost related to the physician and chiropractic practices, had an increase in the cost of services of approximately \$125,000.

The physician and chiropractic practices were sold in January 2001 and 2002 respectively, therefore the September 2002 cost of services to the PT&R segment do not include any activity from these entities. During the nine months ended September 30, 2001, the financial statements include approximately \$367,000 of such costs.

The cost of services relating to the pharmacy segment increased due to the hiring of additional full-time and contract personnel experienced prior to the third quarter of 2002 and higher costs relative to the purchase of prescription drugs. Additionally, sale of growth hormone was dramatically reduced since early august which had significantly lower cost of goods and therefore impacted the overall cost of services of the pharmacy operating unit

The technology segment, excluding the Sleep Disorder Center subsidiary, increased its cost of services during the nine months ended September 30, 2002 as compared to the nine months ended September 30, 2001 by approximately \$10,000. However this increase is reduced by \$2,054,000 of costs classified as costs of services, which were related to product development and technology, which were allocated to Research and Development in the nine months ended September 30, 2001. There were increases in costs in 2002 such as those which were a direct result of an increase in the costs due to the start-up activity required to initiate the outsourcing agreement with IBM for network services of approximately \$420,000. This allocation was consistant with prior quarters accounting.

22

SELLING, GENERAL AND ADMINISTRATIVE

Selling, general and administrative expenses for the nine months ended September 30, 2002 increased by approximately \$845,000, or 7.8%, compared with the same period last year. The increase is due to an increase in bad debt expense caused principally by the allowance required on the funds being held by Medicare. In addition approximately \$3,220,000 of certain costs related to product technology development for the nine months ended September 30, 2001, was allocated to research and development for the technology entity, which was consistent with previous quarters. These increases have been offset by decreases in payroll, contract services and other administrative costs as a direct result of the Company's cost reduction program.

RESEARCH AND DEVELOPMENT

Research and development expenses for the nine months ended September 30, 2002 decreased by approximately \$8,131,000 when compared to the same period last year. The decrease was due to reductions in expenditures for the development of new products that were completed in the fourth quarter of 2001, a shift in the Company's strategic direction related to product development and the inclusion of certain cost of services and selling, general and administrative expenses amounting to \$5,279,000 during the nine months ended September 30, 2001, that were allocated to research and development, because they related to the development of new products.

DEPRECIATION AND AMORTIZATION

Depreciation and amortization decreased, in total, during the nine months ended September 30, 2002 by \$166,000 as compared to the same period last year, primarily as a result of adopting SFAS 142 which no longer requires goodwill to be amortized.

LITIGATION AND LEGAL SETTLEMENT COSTS

During the nine months ended September 30, 2002, the Company has accrued \$960,000 for litigation expenses, offset by \$873,000 from the settlement of certain other litigation which had previously been accrued

OTHER INCOME (EXPENSE)

During the nine months ended September 30, 2002, interest income decreased to \$493,000 compared to \$1,179,000 for the nine months ended September 30, 2001 due to a decrease in available funds for investment purposes.

During the nine months ended September 30, 2002, interest expense increased to \$1,721,000 as compared to \$592,000 for the nine months ended September 30, 2001, primarily due to the increase in senior secured promissory notes issued in 2002.

LIQUIDITY AND CAPITAL RESOURCES

The Company has historically funded its growth from the sale of equity securities and convertible debentures. During the nine months ended September 30, 2002 and 2001, the Company raised approximately \$7,300,000 and \$10,000,000, respectively, through private debt and equity offerings, which the Company has been principally using for working capital purposes. The Company's working capital requirements will continue to be significant through 2002, as the Company continues to eliminate a number of the financial and legal legacy issues incurred prior to 2002. The Company had a working capital deficit of approximately \$11,554,000 as of September 30, 2002. We expect the working capital deficit to continue through the balance of 2002.

Historically, the Company has expended significant amounts to develop its technology segment, including joint venture relationships, introduction into the international market and increasing its

23

research and development and administrative costs. In the first three quarters of 2002, the Company has taken steps to dramatically reduce overall operating costs and substantially increase unit gross margins on hardware sold and revenues received from network operations. The Company has changed its international business model from one focusing on joint ventures to seeking partners for licensing both geographic and technology rights. The Company's overall operating expenses exceed its cash revenues by approximately \$13,169,000 for the nine months ended September 30, 2002, a reduction of \$5,725,000 over 2001. The portion of the Company's operating expenditures that are not funded internally as well as corporate expenditures are currently being funded through private sales of securities.

The Company's continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations, to obtain additional financing, and ultimately, to attain successful operations. The Company is in the process of seeking buyers of its' operating units, seeking additional funding and executing cost reduction measures that will enable it to meet its funding and related commitments. There can be no assurances that such efforts will be successful or will be sufficient to meet the Company's working capital requirements through December 31, 2002.

If the company cannot immediately generate working capital, the company will consider all available options to protect the business, its' shareholders and its' creditors.

Our future capital requirements will depend on numerous factors, including profitable revenue growth, the rate of acceptance of our EHC(TM) Units in the market, our ability to guarantee licensing opportunities for our technology business, our ability to achieve significantly improved gross profits, our ability to achieve revenue and profitability growth from our service segments and our ability to control expenses. The Company expects operating losses to continue through 2002, although at a reduced rate as compare to prior quarters.

In January 2002, the Company issued an 8% debenture in the amount of \$172,200, which was satisfied on April 23, 2002. The debenture was collateralized by a pledge of 400,000 shares of the Company's common stock owned by a former officer and director.

In March 2002, the Company entered into a term sheet with an investor (the "Lender") whereby the Company may borrow up to \$5,000,000 in exchange for senior convertible promissory note(s) (the "Convertible Notes"). The Convertible Notes have a 12-month term and requires interest at 10% per annum, increasing to 15% retroactively upon default. At the election of the Lender, both principal and interest are convertible into the Company's common stock at 85% of the closing bid price on the day prior to conversion, but in no event less than \$0.30 per share or more than \$1.25 per share. The note is secured by the Accounts Receivable of CyberCare, a second position on the accounts receivable of the Physical Therapy subsidiary, subject to the consent of the subsidiary's existing lender, the furniture fixture and equipment of CyberCare and the Physical Therapy Subsidiary, subject to any existing encumbrances, inventory of CyberCare, and the proceeds and collateral securing such proceeds of the October 31, 2000 Promissory Note from Outreach Programs, Inc. The Company issued warrants to purchase 250,000 shares of common stock at 0.75 per share, exercisable within 24 months for each 2,500,000 funded by the Lender. The Company is also liable for a commission (payable in cash and warrants) and the Lender's legal fees in connection with review of the transactional documents and closing of the transaction. All of the underlying shares, whether through conversion of the Convertible Notes or exercise of the warrants, have registration rights. As of May 8, 2002, the Company had issued the Convertible Notes for the entire \$5,000,000 under this commitment as described in the following three paragraphs.

The Company received \$900,000 (less fees of \$100,000) for working capital purposes and issued a \$1,000,000 60-day promissory note dated January 22, 2002 to Dynamic Holdings Corporation and its principal (the "Note"). The note was due on March 22, 2002 and interest was due on the unpaid principal balance at the rate of 8% per annum. The Company refinanced the Note without penalty by issuing a \$1,250,000 convertible promissory note dated April 5, 2002 ("Dynamic Note") which is part of the \$5,000,000 commitment discussed above. The Dynamic Note is secured by the outstanding balance of that certain \$3,225,000 promissory note dated October 31, 2000, given by Outreach Programs, Inc. to the Company in exchange for the sale of 100% of the stock in Carolina Rehab, Inc.

24

The Company received \$228,000 (less fees of \$2,000) for working capital purposes and issued a \$230,000 10-day promissory note dated February 25, 2002 to Dynamic Holdings Corporation. Interest on the unpaid principal balance accrues at the rate of 8% per annum. This note was satisfied through an offset against amounts borrowed under a \$1,250,000 convertible promissory note issued to Manford Investments, LLC (an affiliate of Dynamic Holdings and C.C. Fortune Ventures, LLC) dated April 4, 2002 (the "Manford Note"). The Manford Note is part of the \$5,000,000 commitment discussed above.

The Company received \$2,500,000 (less fees of \$150,000) for working capital purposes and issued a \$2,500,000 senior convertible promissory note dated as of March 7, 2002 with C.C. Fortune Venture, LLC which is part of the \$5,000,000 commitment discussed above.

During the three months ended September 30, 2002, the Company borrowed \$250,000 at 8% per annum from its current Chief Executive Officer and President for working capital purposes. As of September 30, 2002, the Company had repaid this borrowing in full.

On June 2, 2002, the Company issued a \$500,000 one-year Senior Secured Convertible Note to Manford Investments LLC. At the election of Manford, both the principal and interest is convertible into the Company's common stock at 85% of the closing bid price on the day prior to conversion, but in no event less than \$0.20 per share or more than \$0.75 per share. The Company issued warrants to purchase 90,000 shares of common stock at \$0.75 per share, exercisable within 24 months. As of September 30, 2002, the warrants were valued at \$6,000 using the Black-Scholes valuation method.

The Company received \$125,000 for working capital purposes and signed a thirty-day promissory note dated June 26, 2002 to Manford Investments, LLC, which bears interest at 8% per year. The note is currently outstanding and is included in the current portion of notes payable as of September 30, 2002.

On August 15, 2002 the company finalized a definitive agreement with C.C. Fortune Venture, LLC to borrow \$2,000,000 (less fees of \$120,000), for working capital purposes, in exchange for a senior convertible promissory note. The Convertible note has a 24-month term and requires interest at 10% per annum, increasing to 15% retroactively upon default. At the election of the lender, both principal and interest is convertible into the Company's common stock at \$.10 per share. The company issued warrants to purchase 400,000 shares of common stock at \$.20 per share exercisable within 36 months. The note is secured by 100% of the issued and outstanding shares of stock of CyberCare Technologies, Inc. All of the underlying shares, whether through conversion of the Convertible Note or exercise of the warrants, have registration rights. As of October 8, 2002 all of this note has been funded.

On October 21, 2002, the Company received \$95,000 from Manford Investments LLC under a promissory note, which bears interest at 8% per year for working capital purposes. The term was for 30 days, and was repaid on November 1, 2002.

On October 30, 2002, the Company received \$39,500 from Manford Investments LLC under a promissory note, which bears interest at 8% per year for working capital purposes. The term was for 30 days, and was repaid on November 1, 2002.

On November 14, 2002, the Company received \$50,000 from CC Fortune Venture LLC under a \$230,000 promissory note, which bears interest at 8% per year for working capital purposes. The term is for 30 days.

The cash flow of the services subsidiaries are subject to the reimbursement for services rendered from the government, private insurance companies, and directly from patients. If the government or private insurance carriers reduce or delay the payments, this may have a negative effect on our liquidity.

The Nasdaq Stock Market, Inc. ("Nasdaq") notified the Company that on February 20, 2002, the price of the Company's common stock had closed for the previous 30 consecutive trading days below the minimum \$1.00 per share requirement under its Marketplace Rules. In May, 2002, the Company

25

transferred its common stock listing to the Nasdaq SmallCap Market, which provided an extended grace period in which to satisfy the listing requirements for the Company's securities. The Company has until August 19, 2002 to regain compliance under the Nasdaq Marketplace Rules. An additional 180-day grace period may be applicable; provided that the Company meets the initial listing criteria for the SmallCap Market under the Marketplace Rules. The Company may be eligible to transfer back to the Nasdaq National Market if by February 17, 2003 it regains compliance in accordance with the Nasdaq Marketplace Rules.

On August 2, 2002, Nasdaq responded to an inquiry by the company regarding a deficiency in outside directors supporting the Company's Audit Committee activities. Nasdaq agreed with the Company's assertion that it was not in compliance with the audit committee requirements of NASDAQ and needed to remedy the situation. The Company is in the process of adding additional outside directors and has until August 19, 2002 to remedy the deficiency. The Director issue was due on August 16, 2002, but was combined as one requirement by Nasdaq and the Company has until August 19, 2002 to respond.

On August 16, 2002, the Company communicated with Nasdaq on the deficiency issues and Nasdaq indicated that the Company has until August 19, 2002 to respond on both issues. On November 1, 2002, the Company's common stock was delisted from trading, on the NASDAQ national market. The Company's common stock is currently trading on the NASDAQ Over the Counter Bulletin Board.

Except as discussed above, we have no commitments for additional financings or borrowings. We can provide no assurance that additional debt or equity financing will be completed, and if completed, will be on favorable terms. The delisting of the trading of the Company's common stock from the NASDAQ National Market will most likely make it more difficult to obtain capital on terms acceptable to the company. Lower than expected earnings resulting from adverse conditions or otherwise, could restrict our ability to expand our operations, or otherwise fully execute our business plan. Management will explore all available alternatives to preserve our business operations.

Cash used in operating activities was \$7,339,000 and \$21,401,000 for the nine months ended September 30, 2002 and 2001, respectively. The decrease of 65.7%, \$14,062,000, was primarily a result of the Company's ongoing cost reduction program, an increase in accruals for settlement of various litigation, a loss from the sale of Southeast Medical and Tallahassee Sleep Disorder Center, an increase in provision for doubtful accounts, a decrease in revenue from the Pharmacy Care and Physical Therapy segments due to the reduction in customers and clinics, amortization of beneficial conversion feature and discount, and common stock issued for payment of services rendered and interest.

Cash provided by investing activities was \$120,000 for the nine months ended September 30, 2002 compared to cash provided by investing activities of \$868,000 for the nine months ended September 30, 2001. The decrease was primarily a result of repayments of loaned amounts during the nine months ended September 30, 2001 and the reduction in net proceeds from marketable securities, as compared to the current period.

Cash provided by financing activities was \$6,846,000 and \$9,999,000 for the nine months ended September 30, 2002 and 2001, respectively. The decrease was primarily due to funds received in 2001 from the issuance of convertible subordinated debentures and various other promissory notes, offset by direct sales of the Company's common stock in 2002.

Total assets as of September 30, 2002 decreased to \$19,487,000 or 37.6% from December 31, 2001. This decrease was attributable to a reduction in cash as a result of working capital requirements and the sale of Southeast Medical and Tallahassee Sleep Disorder Center. Total cash and cash equivalents as of September 30, 2002, decreased to \$319,000 from \$693,000, as of December 31, 2001. Net accounts receivable decreased \$2,976,000 as of September 30, 2002. Approximately \$470,000 of the decrease in accounts receivable related to the sale of the Southeast Medical and Tallahassee Sleep Disorder Entities, and \$700,000 relating to the increase in the Medicare allowance for the previous mentioned dispute with

the balance due to the reduction in revenues generated from the Physical Therapy and Pharmacy segments. Also, overall assets decreased due to depreciation and amortization of property and equipment and licenses of \$1,522,000.

Total liabilities as of September 30, 2002 increased to \$28,824,000 or 38.5% from \$20,810,000 at December 31, 2001. This increase is primarily due to the issuance of subordinated debentures in the amount of \$7,500,000 and accruals for various lawsuit liabilities.

Working capital deficiency, defined as current assets less current liabilities increased by \$9,398,000 from December 31, 2001, primarily resulting from use of cash to fund operations, the accrual for various lawsuit liabilities, an increase in the allowance for the receivables being held in escrow by Medicare and the issuance of senior secured promissory notes due within one year.

CRITICAL ACCOUNTING POLICIES

The Company's discussion and analysis of its financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related contingent liabilities. On an on-going basis, the Company evaluates its estimates, including those related to revenues, bad debts, inventories, investments, income taxes, and contingencies and litigation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

REVENUE RECOGNITION

The Company generates revenue primarily from the provision of therapy and related services, the sale of prescription drugs and, to a lesser extent, the sale of technology related products and services. The Company recognizes revenue when services have been rendered or delivery has occurred, the price of the product or service is fixed or determinable and collectability is reasonably assured.

The Company's subsidiaries bill Medicare and Medicaid for certain products and services provided. Medicare and Medicaid reimbursements are recognized based on allowable charges. The difference between the established billing rates and contracted or anticipated reimbursement rates is recorded as a contractual allowance and offset against net revenue. These revenues are subject to audit and retroactive adjustment by the respective fiscal intermediaries.

ALLOWANCE FOR CONTRACTUAL ADJUSTMENTS

In order to reduce gross revenue to the estimated net realizable amount due from certain third-party payers, the Company estimates an allowance for contractual adjustments in the period the services are rendered. The allowance for contractual adjustments is reviewed periodically and adjusted in future periods as final settlements with third-party payors are determined.

ALLOWANCE FOR DOUBTFUL ACCOUNTS

The Company maintains an allowance for doubtful accounts based on historical collections of accounts receivable. The Company continually monitors its accounts receivable balances and records a monthly estimate for amounts determined to be uncollectible. This allowance is adjusted periodically for actual amounts deemed uncollectible. EXCESS AND OBSOLETE INVENTORY

27

The Company writes down excess and obsolete inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future product life-cycles, product demand and market conditions. If actual product life cycles, product demand and market conditions are less favorable than those projected, additional inventory write-downs may be required.

ACCOUNTING FOR THE IMPAIRMENT OF LONG-LIVED ASSETS

In August 2001, the Financial Accounting Standards Board issued Statement No. 144 -Accounting for the Impairment or Disposal of Long-Lived Assets (FASB 144), effective for fiscal years beginning after December 15, 2001. This Statement supercedes (FASB 121) - Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed of. FASB 144 retains the fundamental provision of FASB 121 for (a) recognition and measurement of the impairment of long-lived assets to be held and used and (b) measurement of long-lived assets to be held and used and (b) measurement of long-lived assets to be held and used and (b) measurement of long-lived assets of by sale. The Company determined that for the three months ended September 30, 2002, there was an operating impairment on long lived assets of \$885,000 for the Pharmacy Care segment and a \$1,640,000 for the Physical Therapy segment. In addition a cumulative effect impairment was determined on the Technology segment of \$3,793,000, and \$190,000 for the Physical Therapy segment.

Cumulative Effect of Change in Accounting Principle

In June 2001, the Financial Accounting Standards Board ("FASB") issued Statement of Financial Accounting Standards No. 142 ("SFAS 142"), "Goodwill and Other Intangible Assets". SFAS 142 requires that goodwill no longer be amortized to earnings, but instead be reviewed for impairment upon initial adoption of the Statement and on an annual basis going forward. SFAS 142 also requires the Company to complete a transitional goodwill impairment test six months from the date of adoption. The amortization of goodwill ceased upon adoption of SFAS 142 as of January 1, 2002 which will result in a reduction of the company's amortization expense by approximately \$280,000 per year. The Company completed the transitional impairment test of goodwill and indefinite lived intangible assets during the second quarter of 2002. Based upon the results of this test, the Company determined that there was no impairment of goodwill or indefinite lived intangible assets regarding its Pharmacy Care segment, but a potential impairment of goodwill or indefinite lived intangible assets may exist relative to its other two subsidiaries, Physical Therapy & Rehabilitation and CyberCare Technology as of January 1, 2002. The amount of the potential impairment was estimated at 5,394,000 as a result of the transitional impairment test.

During the quarter ended September 30, 2002, the Company noted additional indicators of impairment in its Pharmacy Care and Physical Therapy & Rehabilitation segments. In particular, the Company experienced a significant decline in the operations of these two segments during the third quarter of 2002. As a result, the Company finalized its transitional impairment test and also performed an updated valuation of its intangible assets at September 30, 2002 to determine whether any additional impairment had occurred. As a result of these analyses, the Company determined that its intangible assets were impaired by \$6.5 million at September 30, 2002. Of this amount, approximately \$4.0 million was impaired as of January 1, 2002 and the remainder had become impaired subsequent to that date. The \$3.98 million impairment that existed at January 1,

2002 was recorded as the cumulative effect of change in accounting principle as the result of adopting SFAS 142. The remaining \$2.5 million was recorded in operations as an impairment of long-lived assets during the quarter ended September 30, 2002.

RECENT ACCOUNTING PRONOUNCEMENTS

28

In August 2001, the FASB issued Statement No. 144, ACCOUNTING FOR THE IMPAIRMENT OR DISPOSAL OF LONG-LIVED ASSETS, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets and supercedes FASB Statement No. 121, ACCOUNTING FOR THE IMPAIRMENT OF LONG-LIVED ASSETS AND FOR LONG-LIVED ASSETS TO BE DISPOSED OF, and the accounting and reporting provisions of Accounting Principles Board (APB) Opinion No. 30, REPORTING THE RESULTS OF OPERATIONS REPORTING THE EFFECTS OF DISPOSAL OF A SEGMENT OF A BUSINESS AND EXTRAORDINARY, UNUSUAL AND INFREQUENTLY OCCURRING EVENTS AND TRANSACTIONS. The Company adopted the provisions of FASB Statement No. 144 as of January 1, 2002.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As of September 30, 2002, the Company had outstanding \$17,500,000 aggregate principal amount of convertible subordinated debentures.

The Company's exposure to market rate risk is limited to interest rate risk and risks associated with the price of its common stock. The Company's interest rate risk is limited, since most of the Company's borrowings are at fixed rates. The Company is subject to risk relating to the price of its common stock since the majority of the Company's working capital for 2002 will be derived from the issuance of convertible subordinated notes and the sale of its common stock.

29

PART II

OTHER INFORMATION

Item 1. Legal Proceedings

The Company is engaged in litigation with various parties regarding matters of dispute that have arisen in the normal course of business. The Company is unable to predict the financial impact of pending litigation at this time.

The Company has previously disclosed the 14 purported class action lawsuits that were filed against CyberCare and certain of its executive officers alleging violations of federal securities laws. These lawsuits were consolidated into a single class action lawsuit by the United States District Court for the Southern District of Florida on November 4, 2000. The Consolidated Amended Complaint ("Complaint") principally alleges that the Company and certain of its officers and directors made misrepresentations or omissions regarding the development and future sales forecasts of its Electronic HouseCall(R) system products and revenues of its pharmacy division. On April 19, 2002, counsel for the parties

entered into a Memorandum of Understanding addressing the terms of a settlement (the "Settlement"). The Settlement involves the payment of \$3.1 million, to be provided under an insurance policy, and the issuance by the Company of 5,000,000 shares of stock (subject to certain sale restrictions), without any admission of liability by the Company. The Settlement has been approval by the court. As of September 30, 2002, the Company has accrued \$800,000 for this liability which is included in litigation and legal settlement costs contained in the statement of operations.

Our Physical Therapy and Rehabilitation subsidiary ("PT&R") received a letter from the Center for Medicare and Medicaid Services ("CMS") and its intermediary in April 2001 notifying it of the suspension of Medicare payments. CMS alleged that certain patient complaints, which constituted less than 1% of PT&R's Medicare patients, and other alleged regulatory non-compliance, justified the payment suspension. During the suspension, the Medicare program continued to process PT&R's claims, but held payment in escrow. In August 2001, the suspension was lifted and payment for processed claims was released although approximately \$1,115,000 remained held in escrow, pending further review. CMS completed its review and issued its formal determination in April 2002. CMS determined that approximately \$1,191,000 in overpayment was made. \$76,100 was repaid. PT&R disputes the overpayment and is submitting an appeal to CMS's determination. As of September 30, 2002, the Company has recorded an allowance for the entire overpayment.

A complaint was filed against the Company on August 13, 2001, alleging that the Company breached certain obligations in connection with the removal of a restrictive legend from stock issued to the plaintiff. Mediation was held in March 2002, which resulted in settlement of the dispute. Pursuant to the settlement, the Company issued and registered 869,566 shares of common stock, transferred the assets of the Sleep Disorder Center (previously owned by the plaintiff) back to the plaintiff, and made a cash payment, which the Company's insurance carrier covered, in the amount of \$200,000.

A complaint was filed against the Company by IMRglobal (n/k/a CGI Information Technology Services) on November 21, 2001 in the 6th Judicial Circuit in and for Pinellas County, Florida, alleging that the Company breached its obligations to make payment for software development services of \$1,113,000. A settlement was reached and the Company paid \$150,000 and issued 500,000 shares of its common stock to the plaintiff. The shares were registered, and are subject to certain sale restrictions.

In February 2002, an arbitration panel determined that the Company is responsible for damages and attorneys' fees in connection with the Company's performance under an option agreement. From inception, the Company believed there was no merit to the claim and damages, if any, were covered under an insurance policy. The insurer later asserted that an exclusion from coverage applied. As part of the settlement reached at the mediation of the class action litigation, the Company waived its claim

30

against the insurer for the coverage denial. On April 29, 2002 an Award of Arbitrators was issued and on June 17, 2002, a final judgment was issued for \$1,114,000 plus interest. This amount has been reserved as of September 30, 2002.

A complaint was filed against the Company by Health Hero Network, Inc. on May 31, 2002 in the Superior Court of California in and for the County of Santa Clara, alleging that the Company breached its obligations to make payments for product development services of \$450,000 and seeking additional damages of \$3,388,750. The complaint was served on July 25, 2002 and a demand for

arbitration, with the American Arbitration Association was served on the Company on July 24, 2002. The Company is investigating this matter and will respond to the complaint, and demand for arbitration, after such investigation is complete. The Company believes the claims lack merit and intends to vigorously defend this suit, and counter sue Health Hero Network Inc

The Company is in litigation with a previous employee based upon termination of the employee's employment contract. The Company has accrued its best estimate as of September 30, 2002 for this liability.

Item 2. Changes in Securities and Use of Proceeds

The following is a summary of the Company's equity transactions for the three months ended September 30, 2002 that were not registered under the Securities Act of 1933 As Amended: all transactions were exempt from registration:

All of the securities transactions were registered under the Securities \mbox{Act} of 1933 as amended.

Item 3. Defaults Upon Senior Securities

Currently the Company is in default of its Senior Secured debentures for non payment of interest. Also, the company is in default with its Physical Therapy and Rehabilitation lender for falling below its allowable eligible assets. At this time neither of the debt holders have called the note agreements and they are working with the company to rectify the defaults in a beneficial manner for both the company and the holders of the notes.

Item 4. Submission of Matters to a Vote of Security Holders None

Item 5. Other Information

On December 17, 2001, the Company received an independent appraisal on the leased airplanes. At that date, the average market value of all the planes was \$13,576,000 with a suggested sale price of \$13,832,000.

Due to the Company's current financial situation, the Company was unable to expend resources to maintain the aircraft in accordance with the lease agreement with Aim and fund the required debt service. The Company was notified by the aircraft lender that the Company was in violation of the loan agreements. The company has voluntarily surrendered the aircraft to the lender. As of September 30, 2002, the Company had \$1,268,000 accrual for the estimated future operating losses of Air. Based on this

31

information and a proposal made by the Company to Textron (the lender) as full satisfaction, the Company does not believe an additional reserve is needed for the payment of the leases at this time.

Item 6. Exhibits and Reports on Form 8-K

On April 15, 2002, the Company filed a Current Report on Form 8-K (Item 5) regarding the resignation of its Interim Chairman of the Board.

On April 18, 2002, the Company filed a Current Report on Form 8-K (Item 5) regarding the Company's review of certain former officers' compensation and the election to discontinue payment or provision of all compensation and related benefits to such former officers.

On April 26, 2002, the Company filed a Current Report on Form 8-K (Item 5) regarding the successful mediation settlement of the class action litigation.

On May 2, 2002, the Company filed a Current Report on Form 8-K (Item 5) regarding the refinancing of certain outstanding loans to Dynamic Holdings, LLC by issuing convertible promissory notes.

On June 13, 2002, the Company filed a Current Report on Form 8-K (Item 5) which contained a copy of an open letter from the President and CEO of the Company to the Company's shareholders.

On June 21, 2002, the Company filed a Current Report on Form 8-K (Item 5) regarding the non-binding letter of intent the Company entered into with iBX Group, Inc. to sell the physical therapy and rehabilitation business and the pharmacy business of the Company.

On August 13, 2002, the Company filed a Current Report on Form 8-K (Item 5) regarding the Company's accounts receivable lender declining to provide additional funding above its current obligation. Also, the Company terminated the employment of the president of its Pharmacy segment and that certain key employees resigning upon the president's termination. This situation may have a material adverse effect on the Company's ongoing operation if certain key functions cannot be replaced.

32

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CYBERCARE, INC. ------(Registrant)

/S/ JOSEPH R. FORTE

| NOVEMBER | 19, | 2002 | By: | |
|----------|-----|------|-----|--|
| | | | | |

(Date)

Joseph R. Forte, Chief Executive Officer and President

| NOVEMBER 19, 2002 By: | /S/ ALAN ADELSON |
|-----------------------|--|
| | |
| (Date) | Alan Adelson, Executive Vice President |
| NOVEMBER 19, 2002 By: | /S/ JEFF SCHULMAN |

(Date)

Jeff Schulman, Chief Accounting Officer

33

CERTIFICATIONS

Statement Under Oath Regarding Facts and Circumstances Relating to Exchange Act Filings

I, Joseph Forte, certify that: